1
|
Villain N, Michalon R. What is Alzheimer's disease? An analysis of nosological perspectives from the 20th and 21st centuries. Eur J Neurol 2024:e16302. [PMID: 38618742 DOI: 10.1111/ene.16302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/13/2024] [Revised: 03/28/2024] [Accepted: 03/29/2024] [Indexed: 04/16/2024]
Abstract
BACKGROUND Recent US proposals suggest defining Alzheimer's disease (AD) based on β-amyloidosis alone. This sparked debates that echoed historical ones about the significance of brain lesions and clinical phenotype. METHODS This review covers debates on AD nosology through three key periods: AD's discovery in German-speaking countries in the early 20th century, its redefinition in Anglo-Saxon countries in the 1960s-1980s, and current debates on the biological or clinicobiological definitions of AD. Key players' opinions are focused on. RESULTS At the beginning of the 20th century, AD was defined as a clinicopathological entity. Debates arose around the pathological anchor, which included extended neurofibrillary tangles versus neuritic plaques (Alzheimer vs. Fischer) and its association with senile dementia (Kraepelin). In the 1960s-1980s, the debate shifted towards whether AD could be diagnosed using qualitative or quantitative neuropathological features and whether it was a unique process (Terry and Katzman) or had subtypes (Roth). The current definition proposed by the US Alzheimer's Association is based purely on biological β-amyloid abnormalities and represents a double break: from the historical clinicopathological definition of AD and from the historical emphasis on tau or combined tau and β-amyloid high levels of pathology. Conversely, the clinicobiological proposal of the International Working Group remains aligned with historical concepts of AD. CONCLUSIONS This historical perspective illustrates the unresolved questions surrounding AD pathogenesis, role of lesions, and the clinical phenotype, especially for sporadic cases. The intense nosological debates throughout the history of AD also illustrate the diversity of theoretical frameworks for defining disease in medicine.
Collapse
Affiliation(s)
- Nicolas Villain
- Sorbonne Université, INSERM U1127, CNRS 7225, Institut du Cerveau-ICM, Paris, France
- Department of Neurology, Institute of Memory and Alzheimer's Disease, AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Paris, France
| | - Robin Michalon
- École des Hautes Etudes en Sciences Sociales, Paris, France
- CAK-CRHST - Centre Alexandre Koyré - Centre de Recherche en Histoire des Sciences et des Techniques, Paris, France
| |
Collapse
|
2
|
Garcia MJ, Leadley R, Ross J, Bozeat S, Redhead G, Hansson O, Iwatsubo T, Villain N, Cummings J. Prognostic and Predictive Factors in Early Alzheimer's Disease: A Systematic Review. J Alzheimers Dis Rep 2024; 8:203-240. [PMID: 38405341 PMCID: PMC10894607 DOI: 10.3233/adr-230045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2023] [Accepted: 12/24/2023] [Indexed: 02/27/2024] Open
Abstract
Background Alzheimer's disease (AD) causes progressive decline of cognition and function. There is a lack of systematic literature reviews on prognostic and predictive factors in its early clinical stages (eAD), i.e., mild cognitive impairment due to AD and mild AD dementia. Objective To identify prognostic factors affecting eAD progression and predictive factors for treatment efficacy and safety of approved and/or under late-stage development disease-modifying treatments. Methods Databases were searched (August 2022) for studies reporting prognostic factors associated with eAD progression and predictive factors for treatment response. The Quality in Prognostic Factor Studies tool or the Cochrane risk of bias tool were used to assess risk of bias. Two reviewers independently screened the records. A single reviewer performed data extraction and quality assessment. A second performed a 20% check. Content experts reviewed and interpreted the data collected. Results Sixty-one studies were included. Self-reporting, diagnosis definition, and missing data led to high risk of bias. Population size ranged from 110 to 11,451. Analyses found data indicating that older age was and depression may be associated with progression. Greater baseline cognitive impairment was associated with progression. APOE4 may be a prognostic factor, a predictive factor for treatment efficacy and predicts an adverse response (ARIA). Elevated biomarkers (CSF/plasma p-tau, CSF t-tau, and plasma neurofilament light) were associated with disease progression. Conclusions Age was the strongest risk factor for progression. Biomarkers were associated with progression, supporting their use in trial selection and aiding diagnosis. Baseline cognitive impairment was a prognostic factor. APOE4 predicted ARIA, aligning with emerging evidence and relevant to treatment initiation/monitoring.
Collapse
Affiliation(s)
| | - Regina Leadley
- Mtech Access Ltd, IT Centre, Innovation Way, Heslington, York, UK
| | - Janine Ross
- Mtech Access Ltd, IT Centre, Innovation Way, Heslington, York, UK
| | | | | | - Oskar Hansson
- Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Faculty of Medicine, Lund University, Lund, Sweden
- Memory Clinic, Skåne University Hospital, Lund, Sweden
| | | | - Nicolas Villain
- AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer’s Disease, Paris, France
- Sorbonne Université, INSERM U1127, CNRS 7225, Institut du Cerveau –ICM, Paris, France
| | - Jeffrey Cummings
- Chambers-Grundy Center for TransformativeNeuroscience, Department of Brain Health, School of IntegratedHealth Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA
| |
Collapse
|
3
|
Jacquemin C, Villain N, Azevedo R, Boluda S, Thévenot EA, Fenaille F, Lamari F, Becher F. Evaluation of SP3 for antibody-free quantification of tau in CSF mimic and brain by mass spectrometry. Eur J Mass Spectrom (Chichester) 2024; 30:65-75. [PMID: 38258392 DOI: 10.1177/14690667231218912] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 01/24/2024]
Abstract
Tubulin-associated unit (tau) has an important role in the pathogenesis and the diagnosis of Alzheimer's disease (AD) and other tauopathies. In view of the diversity of tau proteoforms, antibody-free methods represent a good approach for unbiased quantification. We adapted and evaluated the single-pot, solid-phase-enhanced sample-preparation (SP3) protocol for antibody-free extraction of the tau protein in cerebro-spinal fluid (CSF) mimic and in human brain. A total of 13 non-modified peptides were quantified by high-resolution mass spectrometry (HRMS) after digestion of tau by trypsin. We significantly improved the basic SP3 protocol by carefully optimizing the organic solvents and incubation time for tau binding, as well as the digestion step for the release directly from the SP3 beads of the 13 tau peptides. These optimizations proved to be primarily beneficial for the most hydrophilic tau peptides, increasing the sequence coverage of recombinant tau. Mean recovery in CSF mimic of the 13 non-modified peptides was of 53%, with LODs ranging from 0.75 to 10 ng/mL. Next, we tested the optimized SP3 protocol on pathological tau extracted from the soluble fraction from an AD brain sample (middle frontal gyrus). We could successfully identify and quantify biologically relevant tau peptides including representative peptides of two isoforms and two phospho-peptides (pTau217 and pTau181).
Collapse
Affiliation(s)
- Chloé Jacquemin
- Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, Gif-sur-Yvette, France
| | - Nicolas Villain
- Department of Neurology, Institute of Memory and Alzheimer's Disease, Assistance Publique - Hopitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
| | - Rita Azevedo
- Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, Gif-sur-Yvette, France
| | - Susana Boluda
- Department of Neuropathology Raymond Escourolle, Assistance Publique - Hôpitaux de Paris (AP-HP) Sorbonne, Pitié-Salpêtrière, Paris, France
| | - Etienne A Thévenot
- Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, Gif-sur-Yvette, France
| | - François Fenaille
- Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, Gif-sur-Yvette, France
| | - Foudil Lamari
- Service de Biochimie Métabolique, AP-HP Sorbonne, Paris Brain Institute (ICM) Inserm - Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - François Becher
- Département Médicaments et Technologies pour la Santé (DMTS), Université Paris-Saclay, CEA, INRAE, Gif-sur-Yvette, France
| |
Collapse
|
4
|
Bejanin A, Villain N. Posterior cortical atrophy: new insights into treatments and biomarkers for Alzheimer's disease. Lancet Neurol 2024; 23:127-128. [PMID: 38267172 DOI: 10.1016/s1474-4422(23)00501-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/04/2023] [Accepted: 12/07/2023] [Indexed: 01/26/2024]
Affiliation(s)
- Alexandre Bejanin
- Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain; Center of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED), Madrid, Spain.
| | - Nicolas Villain
- AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France; Sorbonne Université, INSERM U1127, CNRS 7225, Institut du Cerveau-ICM, Paris, France
| |
Collapse
|
5
|
Nicolas G, Zaréa A, Lacour M, Quenez O, Rousseau S, Richard AC, Bonnevalle A, Schramm C, Olaso R, Sandron F, Boland A, Deleuze JF, Andriuta D, Anthony P, Auriacombe S, Balageas AC, Ballan G, Barbay M, Béjot Y, Belliard S, Benaiteau M, Bennys K, Bombois S, Boutoleau-Bretonnière C, Branger P, Carlier J, Cartz-Piver L, Cassagnaud P, Ceccaldi MP, Chauviré V, Chen Y, Cogez J, Cognat E, Contegal-Callier F, Corneille L, Couratier P, Cretin B, Crinquette C, Dauriat B, Dautricourt S, de la Sayette V, de Liège A, Deffond D, Demurger F, Deramecourt V, Derollez C, Dionet E, Doco Fenzy M, Dumurgier J, Dutray A, Etcharry-Bouyx F, Formaglio M, Gabelle A, Gainche-Salmon A, Godefroy O, Graber M, Gregoire C, Grimaldi S, Gueniat J, Gueriot C, Guillet-Pichon V, Haffen S, Hanta CR, Hardy C, Hautecloque G, Heitz C, Hourregue C, Jonveaux T, Jurici S, Koric L, Krolak-Salmon P, Lagarde J, Lanoiselée HM, Laurens B, Le Ber I, Le Guyader G, Leblanc A, Lebouvier T, Levy R, Lippi A, Mackowiak MA, Magnin E, Marelli C, Martinaud O, Maureille A, Migliaccio R, Milongo-Rigal E, Mohr S, Mollion H, Morin A, Nivelle J, Noiray C, Olivieri P, Paquet C, Pariente J, Pasquier F, Perron A, Philippi N, Planche V, Pouclet-Courtemanche H, Rafiq M, Rollin-Sillaire A, Roué-Jagot C, Saracino D, Sarazin M, Sauvée M, Sellal F, Teichmann M, Thauvin C, Thomas Q, Tisserand C, Turpinat C, Van Damme L, Vercruysse O, Villain N, Wagemann N, Charbonnier C, Wallon D. Assessment of Mendelian and risk-factor genes in Alzheimer disease: A prospective nationwide clinical utility study and recommendations for genetic screening. Genet Med 2024; 26:101082. [PMID: 38281098 DOI: 10.1016/j.gim.2024.101082] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 01/17/2024] [Accepted: 01/19/2024] [Indexed: 01/29/2024] Open
Abstract
PURPOSE To assess the likely pathogenic/pathogenic (LP/P) variants rates in Mendelian dementia genes and the moderate-to-strong risk factors rates in patients with Alzheimer disease (AD). METHODS We included 700 patients in a prospective study and performed exome sequencing. A panel of 28 Mendelian and 6 risk-factor genes was interpreted and returned to patients. We built a framework for risk variant interpretation and risk gradation and assessed the detection rates among early-onset AD (EOAD, age of onset (AOO) ≤65 years, n = 608) depending on AOO and pedigree structure and late-onset AD (66 < AOO < 75, n = 92). RESULTS Twenty-one patients carried a LP/P variant in a Mendelian gene (all with EOAD, 3.4%), 20 of 21 affected APP, PSEN1, or PSEN2. LP/P variant detection rates in EOAD ranged from 1.7% to 11.6% based on AOO and pedigree structure. Risk factors were found in 69.5% of the remaining 679 patients, including 83 (12.2%) being heterozygotes for rare risk variants, in decreasing order of frequency, in TREM2, ABCA7, ATP8B4, SORL1, and ABCA1, including 5 heterozygotes for multiple rare risk variants, suggesting non-monogenic inheritance, even in some autosomal-dominant-like pedigrees. CONCLUSION We suggest that genetic screening should be proposed to all EOAD patients and should no longer be prioritized based on pedigree structure.
Collapse
Affiliation(s)
- Gaël Nicolas
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France.
| | - Aline Zaréa
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France
| | - Morgane Lacour
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France
| | - Olivier Quenez
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France
| | - Stéphane Rousseau
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France
| | - Anne-Claire Richard
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France
| | - Antoine Bonnevalle
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France; Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France
| | - Catherine Schramm
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Genetics and CNRMAJ, F-76000 Rouen, France
| | - Robert Olaso
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France
| | - Florian Sandron
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France
| | - Anne Boland
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France
| | - Jean-François Deleuze
- Université Paris-Saclay, CEA, Centre National de Recherche en Génomique Humaine (CNRGH), Evry, France
| | - Daniela Andriuta
- Service de Neurologie CHU Amiens et Laboratoire de Neurosciences Fonctionnelles et Pathologies, Université de Picardie Jules Verne, Amiens, France
| | - Pierre Anthony
- Department of Neurology, Hôpitaux Civils de Colmar, F-68000 Colmar, France
| | - Sophie Auriacombe
- Univ. Bordeaux, CNRS UMR 5293, Institut des Maladies Neurodégénératives, Bordeaux, France
| | | | | | - Mélanie Barbay
- Service de Neurologie CHU Amiens et Laboratoire de Neurosciences Fonctionnelles et Pathologies, Université de Picardie Jules Verne, Amiens, France
| | - Yannick Béjot
- Department of Neurology, University Hospital of Dijon, University of Burgundy, Dijon, France
| | - Serge Belliard
- Unité de recherche 1077 INSERM-EPHE-UNICAEN Neuropsychologie & Imagerie de la Mémoire Humaine (NIMH), Caen, France; Centre Mémoire Ressources et Recherche Haute Bretagne, CHU Rennes, Rennes, France
| | - Marie Benaiteau
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Karim Bennys
- Memory Ressources Research Center, Department of Neurology, University Hospital of Montpellier, Montpellier, France
| | - Stéphanie Bombois
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | | | - Pierre Branger
- Department of Neurology, Caen University Hospital, Caen, France
| | - Jasmine Carlier
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Leslie Cartz-Piver
- Memory Ressources Research Center, Department of Neurology, University Hospital of Limoges, France Inserm U1094, IRD U270, EPIMACT, Université of Limoges, Limoges, France
| | | | - Mathieu-Pierre Ceccaldi
- Institute of Neurophysiopathology UMR 7051 Aix Marseille Université & Assistance Publique de Marseille, Marseille, France
| | - Valérie Chauviré
- CMRR, CRMR Neurogénétique, Service de Neurologie, CHU d'ANGERS, Angers, France
| | - Yaohua Chen
- Univ Lille, CHU Lille, Inserm 1172, Memory center, CNRMAJ, LiCEND, Labex DistAlz 59000 Lille, France
| | - Julien Cogez
- Department of Neurology, Caen University Hospital, Caen, France
| | - Emmanuel Cognat
- Cognitive Neurology Center, AP-HP.Nord, Site Lariboisière Fernand-Widal, Paris, France; Université Paris Cité, UMR-S 1144, INSERM, Paris, France
| | | | - Léa Corneille
- Institute of Neurophysiopathology UMR 7051 Aix Marseille Université & Assistance Publique de Marseille, Marseille, France
| | | | - Benjamin Cretin
- CMRR d'Alsace, Service de Neurologie, CHU Strasbourg, Strasbourg, France
| | | | - Benjamin Dauriat
- Service de Génétique Médicale, Hopital Mère-Enfant, CHU Limoges, Limoges, France
| | - Sophie Dautricourt
- CMRR Lyon, Department of Neurology, University Hospital of Lyon, Hospices Civils de Lyon, Lyon, France
| | - Vincent de la Sayette
- Department of Neurology, Caen University Hospital, Caen, France; Normandie UNIV, UNICAEN, PSL Research University, EPHE, INSERM, CHU de Caen, Neuropsychologie et Imagerie de la Mémoire Humaine, Caen, France
| | - Astrid de Liège
- Service de Neurologie, APHP, Hôpital Avicenne, Université Sorbonne Paris Nord, Bobigny, France
| | - Didier Deffond
- CMRR Clermont-Ferrand, Service de Neurologie, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | | | - Vincent Deramecourt
- Univ Lille, CHU Lille, Inserm 1172, Memory center, CNRMAJ, LiCEND, Labex DistAlz 59000 Lille, France
| | | | - Elsa Dionet
- CMRR Clermont-Ferrand, Service de Neurologie, CHU Clermont-Ferrand, Clermont-Ferrand, France
| | - Martine Doco Fenzy
- Nantes Université, CHU Nantes, CNRS, INSERM, l'institut du thorax, Nantes, France; CHU Nantes, Service de Génétique, Nantes, France; CHU Reims, Service de Génétique, Reims, France
| | - Julien Dumurgier
- Cognitive Neurology Center, AP-HP.Nord, Site Lariboisière Fernand-Widal, Paris, France; Université Paris Cité, UMR-S 1144, INSERM, Paris, France
| | - Anaïs Dutray
- Service de Neurologie, Centre Hospitalier Perpignan, Perpignan, France
| | | | - Maïté Formaglio
- CMRR Lyon, Department of Neurology, University Hospital of Lyon, Hospices Civils de Lyon, Lyon, France
| | - Audrey Gabelle
- Memory Ressources Research Center, Department of Neurology, University Hospital of Montpellier, Montpellier, France
| | - Anne Gainche-Salmon
- Centre Mémoire Ressources et Recherche Haute Bretagne, CHU Rennes, Rennes, France
| | - Olivier Godefroy
- Service de Neurologie CHU Amiens et Laboratoire de Neurosciences Fonctionnelles et Pathologies, Université de Picardie Jules Verne, Amiens, France
| | - Mathilde Graber
- Centre mémoire ressources et recherche, CHU Dijon, Dijon, France
| | - Chloé Gregoire
- CHU de Bordeaux, Pôle de Neurosciences Cliniques, Centre Mémoire de Ressources et de Recherche, Bordeaux, France
| | - Stephan Grimaldi
- Institute of Neurophysiopathology UMR 7051 Aix Marseille Université & Assistance Publique de Marseille, Marseille, France
| | - Julien Gueniat
- Centre mémoire ressources et recherche, CHU Dijon, Dijon, France
| | - Claude Gueriot
- Institute of Neurophysiopathology UMR 7051 Aix Marseille Université & Assistance Publique de Marseille, Marseille, France
| | | | - Sophie Haffen
- Centre mémoire Recherche Ressources, Service de Neurologie, CHU Besançon, Besançon, France
| | - Cezara-Roxana Hanta
- Centre Mémoire Ressources et Recherche Haute Bretagne, CHU Rennes, Rennes, France
| | - Clémence Hardy
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France
| | | | - Camille Heitz
- Institut du cerveau Trocadero, Paris, France; Neurology Department, Hôpital Universitaire de Nîmes, Nîmes, France
| | - Claire Hourregue
- Cognitive Neurology Center, AP-HP.Nord, Site Lariboisière Fernand-Widal, Paris, France
| | - Thérèse Jonveaux
- Centre Mémoire de Ressources et de Recherche de Lorraine Service de Neurologie CHRU Nancy, Nancy, France; Laboratoire 2LPN EA 7489 Université de Lorraine, Nancy, France
| | - Snejana Jurici
- Consultation Mémoire, Service de Gériatrie, Centre Hospitalier Perpignan, Perpignan, France
| | - Lejla Koric
- Institute of Neurophysiopathology UMR 7051 Aix Marseille Université & Assistance Publique de Marseille, Marseille, France; Aix-Marseille Univ, UMR 7249, CNRS, Centrale Marseille, Institut Fresnel, Marseille, France
| | - Pierre Krolak-Salmon
- CMRR Lyon, Department of Neurology, University Hospital of Lyon, Hospices Civils de Lyon, Lyon, France
| | - Julien Lagarde
- Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, F-75014, Paris, France; Université Paris-Cité, F-75006 Paris, France; Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, F-91401, Orsay, France
| | | | - Brice Laurens
- CHU de Bordeaux, Pôle de Neurosciences Cliniques, Centre Mémoire de Ressources et de Recherche, Bordeaux, France
| | - Isabelle Le Ber
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | | | - Amélie Leblanc
- Consultations neurologiques, HIA Clermont-Tonnerre, Brest, France; Service de neurologie, CHU Cavale-Blanche, Brest, France
| | - Thibaud Lebouvier
- Univ Lille, CHU Lille, Inserm 1172, Memory center, CNRMAJ, LiCEND, Labex DistAlz 59000 Lille, France
| | - Richard Levy
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | - Anaïs Lippi
- Service de Neurologie, Hopital Gui de Chauliac, CHU de Montpellier, Montpellier, France
| | | | - Eloi Magnin
- Laboratoire de neuroscience, Université de Franche-Comté UFC et Service de Neurologie, CMRR, CHU Besançon, Besançon, France
| | - Cecilia Marelli
- Service de Neurologie, Hopital Gui de Chauliac, CHU de Montpellier, Montpellier, France
| | - Olivier Martinaud
- Department of Neurology, Caen University Hospital, Caen, France; Normandie UNIV, UNICAEN, PSL Research University, EPHE, INSERM, CHU de Caen, Neuropsychologie et Imagerie de la Mémoire Humaine, Caen, France
| | | | - Raffaella Migliaccio
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | - Emilie Milongo-Rigal
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Sophie Mohr
- Centre mémoire ressources et recherche, CHU Dijon, Dijon, France
| | - Hélène Mollion
- CMRR Lyon, Department of Neurology, University Hospital of Lyon, Hospices Civils de Lyon, Lyon, France
| | - Alexandre Morin
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France; Département de Psychiatrie, Centre Hospitalier du Rouvray, Université de Rouen, 76000, Sotteville-lès-Rouen, France
| | | | - Camille Noiray
- Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, F-75014, Paris, France; Université Paris-Cité, F-75006 Paris, France; Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, F-91401, Orsay, France
| | - Pauline Olivieri
- Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, F-75014, Paris, France; Université Paris-Cité, F-75006 Paris, France; Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, F-91401, Orsay, France
| | - Claire Paquet
- Cognitive Neurology Center, AP-HP.Nord, Site Lariboisière Fernand-Widal, Paris, France; Université Paris Cité, UMR-S 1144, INSERM, Paris, France
| | - Jérémie Pariente
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; Toulouse NeuroImaging Center (ToNIC), INSERM-University of Toulouse Paul Sabatier, Toulouse, France
| | - Florence Pasquier
- Univ Lille, CHU Lille, Inserm 1172, Memory center, CNRMAJ, LiCEND, Labex DistAlz 59000 Lille, France
| | - Alexandre Perron
- Department of Neurology, Hôpitaux Civils de Colmar, F-68000 Colmar, France
| | - Nathalie Philippi
- CMRR d'Alsace, Service de Neurologie, CHU Strasbourg, Strasbourg, France
| | - Vincent Planche
- Univ. Bordeaux, CNRS UMR 5293, Institut des Maladies Neurodégénératives, Bordeaux, France; CHU de Bordeaux, Pôle de Neurosciences Cliniques, Centre Mémoire de Ressources et de Recherche, Bordeaux, France
| | | | - Marie Rafiq
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France; Toulouse NeuroImaging Center (ToNIC), INSERM-University of Toulouse Paul Sabatier, Toulouse, France
| | | | - Carole Roué-Jagot
- Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, F-75014, Paris, France; Université Paris-Cité, F-75006 Paris, France; Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, F-91401, Orsay, France
| | - Dario Saracino
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | - Marie Sarazin
- Department of Neurology of Memory and Language, GHU Paris Psychiatrie & Neurosciences, Hôpital Sainte Anne, F-75014, Paris, France; Université Paris-Cité, F-75006 Paris, France; Université Paris-Saclay, BioMaps, Service Hospitalier Frédéric Joliot CEA, CNRS, Inserm, F-91401, Orsay, France
| | - Mathilde Sauvée
- Centre Mémoire de Ressources et de Recherche, Pôle PReNeLe, CHU Grenoble Alpes CS 10226, 38043 Grenoble Cedex 9, France; Unité de recherche mixte Université Grenoble Alpes/Université Savoie Montblanc, CNRS UMR 5115, Laboratoire de Psychologie et Neurocognition (LPNC), 38000 Grenoble, France
| | - François Sellal
- Department of Neurology, Hôpitaux Civils de Colmar, F-68000 Colmar, France; University of Strasbourg, Medicine Faculty, INSERM, U-1118, Strasbourg, France
| | - Marc Teichmann
- AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | - Christel Thauvin
- Genetics Center, University Hospital of Dijon, University of Burgundy, Dijon, France
| | - Quentin Thomas
- Department of Neurology, University Hospital of Dijon, University of Burgundy, Dijon, France; Genetics Center, University Hospital of Dijon, University of Burgundy, Dijon, France
| | - Camille Tisserand
- Neurology Department, Hôpital Pierre-Paul Riquet, Centre Hospitalier Universitaire de Toulouse, Toulouse, France
| | - Cédric Turpinat
- Service de Neurologie, Hopital Gui de Chauliac, CHU de Montpellier, Montpellier, France
| | - Laurène Van Damme
- Service de Neurologie, Centre Hospitalier Perpignan, Perpignan, France
| | | | - Nicolas Villain
- Sorbonne Université, INSERM U1127, CNRS 7235, Institut du Cerveau - ICM, Paris, France; AP-HP Sorbonne Université, Pitié-Salpêtrière Hospital, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France
| | | | - Camille Charbonnier
- Univ Rouen Normandie, Inserm U1245 and CHU Rouen, Department of Biostatistics and CNRMAJ, F-76000 Rouen, France
| | - David Wallon
- Univ Rouen Normandie, Normandie Univ, Inserm U1245 and CHU Rouen, Department of Neurology and CNRMAJ, F-76000 Rouen, France
| |
Collapse
|
6
|
Villain N. [How to deal with memory complaints]. Rev Prat 2023; 73:1090-1094. [PMID: 38294474] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/01/2024]
Abstract
HOW TO DEAL WITH MEMORY COMPLAINTS. Memory complaint is a common condition in the general population and can indicate normal brain aging as well as incurable neurodegenerative disease or curable disorders. Therefore, the role of any primary care physician is crucial for the referral to further investigations. Furthermore, the pitfall of underdiagnosis, often related to the current incurability of the suspected cause, is contrary to all current guidelines. When facing a memory complaint, the primary care consultation has four objectives: to identify the possible red flags amongst the memory complaint and the memory complaint severity, to objectify a neurocognitive disorder associated with the memory complaint using cognitive tests, to search for associated signs, and to screen for obvious, frequent, and curable causes of memory complaint. The article is intended to be a practical tool aligned with the 2018 French multidisciplinary recommendations regarding the graded and personalized strategy for diagnosing neurocognitive disorders. It details the possibly worrisome elements to be collected in the history, the elements that need special attention or assessment, and finally, the course of action to be taken after a primary care consultation.
Collapse
Affiliation(s)
- Nicolas Villain
- Hôpital La Pitié- Salpêtrière, département de neurologie, Institut de la mémoire et de la maladie d'Alzheimer, AP-HP, Paris, France. Sorbonne Université, Inserm U1127, CNRS 7225, Institut du cerveau et de la moelle épinière, Paris, France
| |
Collapse
|
7
|
Razafimahatratra S, Guieysse T, Lejeune FX, Houot M, Medani T, Dreyfus G, Klarsfeld A, Villain N, Pereira FR, La Corte V, George N, Pantazis D, Andrade K. Can a failure in the error-monitoring system explain unawareness of memory deficits in Alzheimer's disease? Cortex 2023; 166:428-440. [PMID: 37423786 DOI: 10.1016/j.cortex.2023.05.014] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2022] [Revised: 03/13/2023] [Accepted: 05/11/2023] [Indexed: 07/11/2023]
Abstract
Unawareness of memory deficits is an early manifestation in patients with Alzheimer's disease (AD), which often delays diagnosis. This intriguing behavior constitutes a form of anosognosia, whose neural mechanisms remain largely unknown. We hypothesized that anosognosia may depend on a critical synaptic failure in the error-monitoring system, which would prevent AD patients from being aware of their own memory impairment. To investigate, we measured event-related potentials (ERPs) evoked by erroneous responses during a word memory recognition task in two groups of amyloid positive individuals with only subjective memory complaints at study entry: those who progressed to AD within the five-year study period (PROG group), and those who remained cognitively normal (CTRL group). A significant reduction in the amplitude of the positivity error (Pe), an ERP related to error awareness, was observed in the PROG group at the time of AD diagnosis (vs study entry) in intra-group analysis, as well as when compared with the CTRL group in inter-group analysis, based on the last EEG acquisition for all subjects. Importantly, at the time of AD diagnosis, the PROG group exhibited clinical signs of anosognosia, overestimating their cognitive abilities, as evidenced by the discrepancy scores obtained from caregiver/informant vs participant reports on the cognitive subscale of the Healthy Aging Brain Care Monitor. To our knowledge, this is the first study to reveal the emergence of a failure in the error-monitoring system during a word memory recognition task at the early stages of AD. This finding, along with the decline of awareness for cognitive impairment observed in the PROG group, strongly suggests that a synaptic dysfunction in the error-monitoring system may be the critical neural mechanism at the origin of unawareness of deficits in AD.
Collapse
Affiliation(s)
- Solofo Razafimahatratra
- Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - Thomas Guieysse
- Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - François-Xavier Lejeune
- Sorbonne Université, Paris Brain Institute (ICM Institut du Cerveau), AP-HP, INSERM, CNRS, University Hospital Pitié-Salpêtrière, Paris, France; Paris Brain Institute's Data and Analysis Core, University Hospital Pitié-Salpêtrière, Paris, France
| | - Marion Houot
- Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France; Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière Hospital, Paris, France; Clinical Investigation Centre, Institut du Cerveau et de la Moelle épinière (ICM), Pitié-Salpêtrière Hospital Paris, France
| | - Takfarinas Medani
- Signal & Image Processing Institute, University of Southern California, Los Angeles, CA 90089, USA
| | | | - André Klarsfeld
- Laboratory of Brain Plasticity, CNRS UMR 8249, ESPCI Paris - PSL, Paris, France
| | - Nicolas Villain
- Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - Filipa Raposo Pereira
- Brain & Spine Institute, ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Centre MEG-EEG, F-75013, Paris, France
| | - Valentina La Corte
- Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France
| | - Nathalie George
- Brain & Spine Institute, ICM, INSERM U 1127, CNRS UMR 7225, Sorbonne Université, Centre MEG-EEG, F-75013, Paris, France
| | - Dimitrios Pantazis
- McGovern Institute for Brain Research, Massachusetts Institute of Technology, Cambridge, MA, USA
| | - Katia Andrade
- Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, AP-HP, Pitié-Salpêtrière Hospital, Paris, France; Laboratory of Brain Plasticity, CNRS UMR 8249, ESPCI Paris - PSL, Paris, France; FrontLab, Paris Brain Institute, ICM, Pitié Salpêtrière GH, 47 Bd de l'Hôpital, 75013, Paris, France.
| |
Collapse
|
8
|
Liu KY, Villain N, Ayton S, Ackley SF, Planche V, Howard R, Thambisetty M. Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease. Brain Commun 2023; 5:fcad175. [PMID: 37389302 PMCID: PMC10306158 DOI: 10.1093/braincomms/fcad175] [Citation(s) in RCA: 12] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2023] [Revised: 05/09/2023] [Accepted: 06/01/2023] [Indexed: 07/01/2023] Open
Abstract
The clinical benefit associated with anti-amyloid immunotherapies, a new class of drugs for the treatment of Alzheimer's disease, is predicated on their ability to modify disease course by lowering brain amyloid levels. At the time of writing, two amyloid-lowering antibodies, aducanumab and lecanemab, have obtained United States Food and Drug Administration accelerated approval, with further agents of this class in the Alzheimer's disease treatment pipeline. Based on limited published clinical trial data to date, regulators, payors and physicians will need to assess their efficacy, clinical effectiveness and safety, as well as cost and accessibility. We propose that attention to three important questions related to treatment efficacy, clinical effectiveness and safety should guide evidence-based consideration of this important class of drugs. These are: (1) Were trial statistical analyses appropriate and did they convincingly support claims of efficacy? (2) Do reported treatment effects outweigh safety concerns and are they generalizable to a representative clinical population of people with Alzheimer's disease? and (3) Do the data convincingly demonstrate disease course modification, suggesting that increasing clinical benefits beyond the duration of the trials are likely? We suggest specific approaches to interpreting trial results for these drugs and highlight important areas of uncertainty where additional data and a cautious interpretation of existing results is warranted. Safe, effective and accessible treatments for Alzheimer's disease are eagerly awaited by millions of patients and their caregivers worldwide. While amyloid-targeting immunotherapies may be promising disease-modifying Alzheimer's disease treatments, rigorous and unbiased assessment of clinical trial data is critical to regulatory decision-making and subsequently determining their provision and utility in routine clinical practice. Our recommendations provide a framework for evidence-based appraisal of these drugs by regulators, payors, physicians and patients.
Collapse
Affiliation(s)
- Kathy Y Liu
- Division of Psychiatry, University College London, London W1T 7NF, UK
| | - Nicolas Villain
- AP-HP.Sorbonne Université, Institut de la Mémoire et de la Maladie d’Alzheimer, Département de Neurologie, Hôpital Pitié-Salpêtrière, 75013 Paris, France
- Sorbonne Université, Institut national de la Santé et de la Recherche Medical (INSERM) U1127, Centre National de la Recherche Scientifique (CNRS) 7225, Institut du Cerveau—ICM, 75013 Paris, France
| | - Scott Ayton
- Melbourne Dementia Research Centre, Florey Institute of Neuroscience and Mental Health, The University of Melbourne, Parkville, VIC 3052, Australia
| | - Sarah F Ackley
- Department of Epidemiology and Biostatistics, University of California San Francisco, San Francisco, CA 94158, USA
| | - Vincent Planche
- Univ. Bordeaux, CNRS, UMR 5293, Institut des Maladies Neurodégénératives, F-33000 Bordeaux, France
- Centre Mémoire Ressources Recherches, Pôle de Neurosciences Cliniques, CHU de Bordeaux, F-33000 Bordeaux, France
| | - Robert Howard
- Division of Psychiatry, University College London, London W1T 7NF, UK
| | - Madhav Thambisetty
- Correspondence to: Madhav Thambisetty, MD, PhD Clinical and Translational Neuroscience Section, Laboratory of Behavioral Neuroscience National Institute on Aging, Baltimore, MD 21224, USA E-mail:
| |
Collapse
|
9
|
Nedelec T, Couvy-Duchesne B, Darves-Bornoz A, Couronne R, Monnet F, Gantzer L, Lekens B, Wu Y, Villain N, Schrag A, Durrleman S, Corvol JC. A comparison between early presentation of dementia with Lewy Bodies, Alzheimer's disease and Parkinson's disease: evidence from routine primary care and UK Biobank data. Ann Neurol 2023. [PMID: 37098633 DOI: 10.1002/ana.26670] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/10/2022] [Revised: 03/31/2023] [Accepted: 04/17/2023] [Indexed: 04/27/2023]
Abstract
OBJECTIVE To simultaneously contrast prediagnostic clinical characteristics of individuals with a final diagnosis of dementia with Lewy Bodies, Parkinson's disease, Alzheimer's disease compared to controls without neurodegenerative disorders. METHODS Using the longitudinal THIN database in the UK, we tested the association of each neurodegenerative disorder with a selected list of symptoms and broad families of treatments, and compared the associations between disorders to detect disease-specific effects. We replicated the main findings in the UK Biobank. RESULTS We used data of 28,222 patients with PD, 20,214 with AD, 4,682 with DLB and 20,214 controls. All neurodegenerative disorders were significantly associated with the presence of multiple clinical characteristics before their diagnosis including sleep disorders, falls, psychiatric symptoms and autonomic dysfunctions. When comparing DLB patients with patients with PD and AD patients, falls, psychiatric symptoms and autonomic dysfunction were all more strongly associated with DLB in the five years preceding the first neurodegenerative diagnosis. The use of statins was lower in patients who developed PD and higher in patients who developed DLB compared to AD. In PD patients, the use of statins was associated with the development of dementia in the five years following PD diagnosis. INTERPRETATION Prediagnostic presentations of falls, psychiatric symptoms and autonomic dysfunctions were more strongly associated with DLB than PD and AD. This study also suggests that whilst several associations with medications are similar in neurodegenerative disorders, statin usage is negatively associated with Parkinson's Disease but positively with DLB and AD as well as development of dementia in PD. This article is protected by copyright. All rights reserved.
Collapse
Affiliation(s)
- Thomas Nedelec
- Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, Inria, Paris, France
| | - Baptiste Couvy-Duchesne
- Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, Inria, Paris, France
- Institute for Molecular Bioscience, the University of Queensland, St Lucia, Queensland, Australia
| | - Aube Darves-Bornoz
- Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, Inria, Paris, France
| | - Raphaël Couronne
- Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, Inria, Paris, France
| | | | | | | | - Yeda Wu
- Institute for Molecular Bioscience, the University of Queensland, St Lucia, Queensland, Australia
| | - Nicolas Villain
- Department of Neurology, Assistance Publique-Hôpitaux de Paris, Paris, France
| | - Anette Schrag
- Department of Clinical Neurosciences, UCL Queen Square Institute of Neurology, University College London, UK
| | - Stanley Durrleman
- Sorbonne Université, Paris Brain Institute - ICM, Inserm, CNRS, Inria, Paris, France
| | | |
Collapse
|
10
|
Planche V, Villain N. Advocating for Demonstration of Disease Modification-Have We Been Approaching Clinical Trials in Early Alzheimer Disease Incorrectly? JAMA Neurol 2023:2803745. [PMID: 37093582 DOI: 10.1001/jamaneurol.2023.0815] [Citation(s) in RCA: 7] [Impact Index Per Article: 7.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/25/2023]
Abstract
This Viewpoint discusses the benefits of clinical trials with a delayed-start design and analysis of downstream biomarkers to examine whether antimyeloid immunotherapy changes the course of early Alzheimer disease.
Collapse
Affiliation(s)
- Vincent Planche
- Centre National de la Recherche Scientifique, Université de Bordeaux, Institut des Maladies Neurodégéneratives, Bordeaux, France
- Centre Mémoire Ressources Recherches, Pôle de Neurosciences Cliniques, Centre Hospitalier Universitaire de Bordeaux, Bordeaux, France
| | - Nicolas Villain
- AP-HP.Sorbonne Université, Institut de la Mémoire et de la Maladie d'Alzheimer, Département de Neurologie, Hôpital Pitié-Salpêtrière, Paris, France
- Sorbonne Université, Institut national de la Santé et de la Recherche Medical (INSERM) U1127, Centre National de la Recherche Scientifique (CNRS) 7225, Institut du Cerveau-ICM, Paris, France
| |
Collapse
|
11
|
Lesoil C, Bombois S, Guinebretiere O, Houot M, Bahrami M, Levy M, Genthon R, Bozon F, Jean-Marie H, Epelbaum S, Foulon P, Villain N, Dubois B. Validation study of "Santé-Cerveau", a digital tool for early cognitive changes identification. Alzheimers Res Ther 2023; 15:70. [PMID: 37013590 PMCID: PMC10068729 DOI: 10.1186/s13195-023-01204-x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/05/2022] [Accepted: 03/11/2023] [Indexed: 04/05/2023]
Abstract
BACKGROUND There is a need for a reliable, easy-to-use, widely available, and validated tool for timely cognitive impairment identification. We created a computerized cognitive screening tool (Santé-Cerveau digital tool (SCD-T)) including validated questionnaires and the following neuropsychological tests: 5 Word Test (5-WT) for episodic memory, Trail Making Test (TMT) for executive functions, and a number coding test (NCT) adapted from the Digit Symbol Substitution Test for global intellectual efficiency. This study aimed to evaluate the performance of SCD-T to identify cognitive deficit and to determine its usability. METHODS Three groups were constituted including 65 elderly Controls, 64 patients with neurodegenerative diseases (NDG): 50 AD and 14 non-AD, and 20 post-COVID-19 patients. The minimum MMSE score for inclusion was 20. Association between computerized SCD-T cognitive tests and their standard equivalent was assessed using Pearson's correlation coefficients. Two algorithms (a simple clinician-guided algorithm involving the 5-WT and the NCT; and a machine learning classifier based on 8 scores from the SCD-T tests extracted from a multiple logistic regression model, and data from the SCD-T questionnaires) were evaluated. The acceptability of SCD-T was investigated through a questionnaire and scale. RESULTS AD and non-AD participants were older (mean ± standard deviation (SD): 72.61 ± 6.79 vs 69.91 ± 4.86 years old, p = 0.011) and had a lower MMSE score (Mean difference estimate ± standard error: 1.74 ± 0.14, p < 0.001) than Controls; post-COVID-19 patients were younger than Controls (mean ± SD: 45.07 ± 11.36 years old, p < 0.001). All the computerized SCD-T cognitive tests were significantly associated with their reference version. In the pooled Controls and NDG group, the correlation coefficient was 0.84 for verbal memory, -0.60 for executive functions, and 0.72 for global intellectual efficiency. The clinician-guided algorithm demonstrated 94.4% ± 3.8% sensitivity and 80.5% ± 8.7% specificity, and the machine learning classifier 96.8% ± 3.9% sensitivity and 90.7% ± 5.8% specificity. The acceptability of SCD-T was good to excellent. CONCLUSIONS We demonstrate the high accuracy of SCD-T in screening cognitive disorders and its good acceptance even in individuals with prodromal and mild dementia stages. SCD-T would be useful in primary care to faster refer subjects with significant cognitive impairment (and limit unnecessary referrals) to specialized consultation, improve the AD care pathway and the pre-screening in clinical trials.
Collapse
Affiliation(s)
- Constance Lesoil
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | - Stéphanie Bombois
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
- INSERM U1171 - Degenerative and Vascular Cognitive Disorders, University of Lille, Lille, France
| | - Octave Guinebretiere
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | - Marion Houot
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
- Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière, Institut du Cerveau - Paris Brain Institute - ICM, Paris, France
| | - Mahsa Bahrami
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | - Marcel Levy
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | - Rémy Genthon
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | - Frédérique Bozon
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
| | | | - Stéphane Epelbaum
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
- Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière, Institut du Cerveau - Paris Brain Institute - ICM, Paris, France
| | | | - Nicolas Villain
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France
- Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière, Institut du Cerveau - Paris Brain Institute - ICM, Paris, France
- Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| | - Bruno Dubois
- Assistance Publique-Hôpitaux de Paris (AP-HP), Department of Neurology, Institute of Memory and Alzheimer's Disease (IM2A), Paris, France.
- Centre of Excellence of Neurodegenerative Disease (CoEN), AP-HP, Pitié-Salpêtrière, Institut du Cerveau - Paris Brain Institute - ICM, Paris, France.
- Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France.
| |
Collapse
|
12
|
Villain N, Planche V, Levy R. Immunothérapies anti-amyloïdes à forte clairance (IAAFC) dans la maladie d’Alzheimer (MA) au stade précoce : méta-analyse, scénarios possibles, recommandations d’utilisation, mise en œuvre et considérations éthiques en cas d’AMM en France. Rev Neurol (Paris) 2023. [DOI: 10.1016/j.neurol.2023.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
13
|
Salardaine Q, Shor N, Villain N, Bozon F, Schiff M, Brassier A, Nadjar Y. Troubles cognitifs dans la xanthomatose cérébrotendineuse : une étude de cohorte pédiatrique et adulte. Rev Neurol (Paris) 2023. [DOI: 10.1016/j.neurol.2023.01.073] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
|
14
|
Frisoni GB, Altomare D, Ribaldi F, Villain N, Brayne C, Mukadam N, Abramowicz M, Barkhof F, Berthier M, Bieler-Aeschlimann M, Blennow K, Brioschi Guevara A, Carrera E, Chételat G, Csajka C, Demonet JF, Dodich A, Garibotto V, Georges J, Hurst S, Jessen F, Kivipelto M, Llewellyn DJ, McWhirter L, Milne R, Minguillón C, Miniussi C, Molinuevo JL, Nilsson PM, Noyce A, Ranson JM, Grau-Rivera O, Schott JM, Solomon A, Stephen R, van der Flier W, van Duijn C, Vellas B, Visser LN, Cummings JL, Scheltens P, Ritchie C, Dubois B. Dementia prevention in memory clinics: recommendations from the European task force for brain health services. Lancet Reg Health Eur 2023; 26:100576. [PMID: 36895446 PMCID: PMC9989648 DOI: 10.1016/j.lanepe.2022.100576] [Citation(s) in RCA: 23] [Impact Index Per Article: 23.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/16/2022] [Revised: 12/09/2022] [Accepted: 12/15/2022] [Indexed: 02/04/2023]
Abstract
Observational population studies indicate that prevention of dementia and cognitive decline is being accomplished, possibly as an unintended result of better vascular prevention and healthier lifestyles. Population aging in the coming decades requires deliberate efforts to further decrease its prevalence and societal burden. Increasing evidence supports the efficacy of preventive interventions on persons with intact cognition and high dementia risk. We report recommendations for the deployment of second-generation memory clinics (Brain Health Services) whose mission is evidence-based and ethical dementia prevention in at-risk individuals. The cornerstone interventions consist of (i) assessment of genetic and potentially modifiable risk factors including brain pathology, and risk stratification, (ii) risk communication with ad-hoc protocols, (iii) risk reduction with multi-domain interventions, and (iv) cognitive enhancement with cognitive and physical training. A roadmap is proposed for concept validation and ensuing clinical deployment.
Collapse
Affiliation(s)
- Giovanni B. Frisoni
- Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva Geneva, Switzerland
| | - Daniele Altomare
- Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva Geneva, Switzerland
| | - Federica Ribaldi
- Memory Center, Department of Rehabilitation and Geriatrics, University Hospitals and University of Geneva Geneva, Switzerland
| | - Nicolas Villain
- Institut de la Mémoire et de la Maladie d’Alzheimer, IM2A, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, Paris, France
- Institut du Cerveau et de la Moelle Épinière, UMR-S975, INSERM, Paris, France
| | - Carol Brayne
- Cambridge Public Health, University of Cambridge, Cambridge, UK
| | - Naaheed Mukadam
- Division of Psychiatry, University College London, London, UK
| | - Marc Abramowicz
- Genetic Medicine, Diagnostics Dept, University Hospitals and University of Geneva, Geneva, Switzerland
| | - Frederik Barkhof
- Radiology & Nuclear Medicine, Amsterdam University Medical Centers, Amsterdam, the Netherlands
- Queen Square Institute of Neurology, University College London, London, UK
| | - Marcelo Berthier
- Unit of Cognitive Neurology and Aphasia, Centro de Investigaciones Médico-Sanitarias (CIMES), University of Malaga, Malaga, Spain
| | - Melanie Bieler-Aeschlimann
- Leenaards Memory Centre, Department of Clinical Neurosciences, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
- Infections Disease Service, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
| | - Kaj Blennow
- Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, University of Gothenburg, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Andrea Brioschi Guevara
- Leenaards Memory Centre, Department of Clinical Neurosciences, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
- Faculty of Psychology and Educational Sciences, University of Geneva, Geneva, Switzerland
| | - Emmanuel Carrera
- Stroke Center, Department of Clinical Neurosciences, University Hospitals and University of Geneva, Geneva, Switzerland
| | - Gaël Chételat
- Normandie University, UNICAEN, INSERM, U1237, PhIND Physiopathology and Imaging of Neurological Disorders, Cyceron, Caen, France
| | - Chantal Csajka
- Center of Research and Innovation in Clinical Pharmaceutical Sciences, University Hospital and University of Lausanne, Lausanne, Switzerland
| | - Jean-François Demonet
- Leenaards Memory Centre, Department of Clinical Neurosciences, University Hospital of Lausanne (CHUV), Lausanne, Switzerland
- French Clinical Research Infrastructure Network, INSERM, University Hospital of Toulouse, France
| | - Alessandra Dodich
- Center for Mind/Brain Sciences (CIMeC), University of Trento, Rovereto, Italy
| | - Valentina Garibotto
- Division of Nuclear Medicine and Molecular Imaging, University Hospitals of Geneva and NIMTLab, University of Geneva, Geneva, Switzerland
| | | | - Samia Hurst
- Institute for Ethics, History, and the Humanities, Faculty of Medicine, University of Geneva, Geneva, Switzerland
| | - Frank Jessen
- Department of Psychiatry, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany
- German Center for Neurodegenerative Diseases (DZNE), Bonn-Cologne, Germany
- Excellence Cluster Cellular Stress Responses in Aging-Related Diseases (CECAD), Medical Faculty, University of Cologne, Germany
| | - Miia Kivipelto
- Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
- Institute of Public Health and Clinical Nutrition, University of Eastern Finland, Kuopio, Finland
- Theme Aging, Karolinska University Hospital, Stockholm, Sweden
- The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
| | - David J. Llewellyn
- College of Medicine and Health, University of Exeter, UK
- Alan Turing Institute, Exeter, UK
| | - Laura McWhirter
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, Scotland, UK
| | - Richard Milne
- Cambridge Public Health, University of Cambridge, Cambridge, UK
- Engagement and Society, Wellcome Connecting Science, Hinxton, UK
| | - Carolina Minguillón
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
- IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain
- CIBER Fragilidad y Envejecimiento Saludable (CIBERFES), Madrid, Spain
| | - Carlo Miniussi
- Center for Mind/Brain Sciences (CIMeC), University of Trento, Rovereto, Italy
- Centre for Medical Sciences (CISMed), University of Trento, Rovereto, Italy
| | - José Luis Molinuevo
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
- H. Lundbeck A/S, Denmark
| | - Peter M. Nilsson
- Department of Clinical Science, Lund University, Sweden
- Department of Internal Medicine, Skåne University Hospital, Malmö, Sweden
| | - Alastair Noyce
- Preventive Neurology Unit, Wolfson Institute of Population Health, Queen Mary University of London, London, UK
| | | | - Oriol Grau-Rivera
- Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain
| | - Jonathan M. Schott
- Dementia Research Centre, UCL Queen Square Institute of Neurology, London, UK
| | - Alina Solomon
- The Ageing Epidemiology Research Unit, School of Public Health, Imperial College London, London, UK
- Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
- Division of Clinical Geriatrics, NVS, Karolinska Institutet, Stockholm, Sweden
| | - Ruth Stephen
- Institute of Clinical Medicine, University of Eastern Finland, Kuopio, Finland
| | - Wiesje van der Flier
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands
- Amsterdam Neuroscience, Neurodegeneration, Amsterdam, the Netherlands
- Epidemiology and Data Science, Vrije Universiteit Amsterdam, Amsterdam UMC location VUmc, Amsterdam, the Netherlands
| | - Cornelia van Duijn
- Department of Epidemiology, Erasmus University Medical Center, Rotterdam, the Netherlands
- Clinical Trial Service Unit and Epidemiological Studies Unit, Nuffield Department of Population Health, University of Oxford, Oxford, UK
| | - Bruno Vellas
- Gerontopole and Alzheimer's Disease Research and Clinical Center, Toulouse University Hospital, Toulouse, France
| | - Leonie N.C. Visser
- Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden
- Department of Medical Psychology, Amsterdam Public Health Research Institute, Amsterdam UMC, Amsterdam, the Netherlands
| | - Jeffrey L. Cummings
- Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada, Las Vegas, NV, USA
| | - Philip Scheltens
- Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience, Amsterdam UMC, Amsterdam, the Netherlands
- EQT Life Sciences, Amsterdam, the Netherlands
| | - Craig Ritchie
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Bruno Dubois
- Institut de la Mémoire et de la Maladie d’Alzheimer, IM2A, Groupe Hospitalier Pitié-Salpêtrière, Sorbonne Université, Paris, France
- Institut du Cerveau et de la Moelle Épinière, UMR-S975, INSERM, Paris, France
| |
Collapse
|
15
|
Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 1: Meta-analysis and review of efficacy and safety data, and medico-economical aspects. Rev Neurol (Paris) 2022; 178:1011-1030. [PMID: 36184326 DOI: 10.1016/j.neurol.2022.06.012] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 04/25/2022] [Accepted: 06/15/2022] [Indexed: 12/14/2022]
Abstract
In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results on a putative biological surrogate marker. This approval has raised an unprecedented controversy. It was followed by a refusal of the European Medicine Agency, which does not allow the marketing of drugs solely on biological arguments and raised safety issues, and important US coverage limitations by the Centers for Medicare & Medicaid Services. Two other anti-amyloid immunotherapies showed significant results regarding a clinical outcome in phase 2 trials, and five drugs are being studied in phase 3 trials. Compared to those tested in previous trials of the 2010s, the common feature and novelty of these anti-amyloid immunotherapies is their ability to induce a high clearance of amyloid load, as measured with positron emission tomography, in the brain of early-stage biomarker-proven AD patients. Here, we review the available evidence regarding efficacy and safety data and medico-economical aspects for high-clearance anti-amyloid immunotherapies. We also perform frequentist and Bayesian meta-analyses of the clinical efficacy and safety of the highest dose groups from the two aducanumab phase 3 trials and the donanemab and lecanemab phase 2 trials. When pooled together, the data from high-clearance anti-amyloid immunotherapies trials confirm a statistically significant clinical effect of these drugs on cognitive decline after 18 months (difference in cognitive decline measured with CDR-SB after 18 months between the high dose immunotherapy groups vs. placebo = -0.24 points; P=0.04, frequentist random-effect model), with results on ADAS-Cog being the most statistically robust. However, this effect remains below the previously established minimal clinically relevant values. In parallel, the drugs significantly increased the occurrence of amyloid-related imaging abnormalities-edema (ARIA-E: risk ratio=13.39; P<0.0001), ARIA-hemorrhage (risk ratio=2.78; P=0.0002), and symptomatic and serious ARIA (7/1321=0.53% in the high dose groups versus 0/1446 in the placebo groups; risk ratio=6.44; P=0.04). The risk/benefit ratio of high-clearance immunotherapies in early AD is so far questionable after 18 months. Identifying subgroups of better responders, the perspective of combination therapies, and a longer follow-up may help improve their clinical relevance. Finally, the preliminary evidence from medico-economical analyses seems to indicate that the current cost of aducanumab in the US is not in reasonable alignment with its clinical benefits.
Collapse
Affiliation(s)
- N Villain
- Assistance Publique - Hôpitaux de Paris, Department of Neurology, Institute of Memory and Alzheimer's Disease, Pitié-Salpêtrière Hospital, Paris, France; Sorbonne Université, Inserm U1127, CNRS 7225, Institut du Cerveau - ICM, Paris, France.
| | - V Planche
- CNRS, IMN, UMR 5293, University Bordeaux, 33000 Bordeaux, France; Pôle de Neurosciences Cliniques, Centre Mémoire Ressources Recherches, CHU de Bordeaux, 33000 Bordeaux, France
| | - R Levy
- Assistance Publique - Hôpitaux de Paris, Department of Neurology, Institute of Memory and Alzheimer's Disease, Pitié-Salpêtrière Hospital, Paris, France; Sorbonne Université, Inserm U1127, CNRS 7225, Institut du Cerveau - ICM, Paris, France
| |
Collapse
|
16
|
Villain N, Planche V, Levy R. High-clearance anti-amyloid immunotherapies in Alzheimer's disease. Part 2: putative scenarios and timeline in case of approval, recommendations for use, implementation, and ethical considerations in France. Rev Neurol (Paris) 2022; 178:999-1010. [PMID: 36336488 DOI: 10.1016/j.neurol.2022.08.002] [Citation(s) in RCA: 8] [Impact Index Per Article: 4.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 07/20/2022] [Accepted: 08/13/2022] [Indexed: 11/06/2022]
Abstract
In 2021, aducanumab, an immunotherapy targeting amyloid-β, was approved for Alzheimer's disease (AD) by the US Food and Drug Administration thanks to positive results on a putative biological surrogate marker. This approval has raised an unprecedented controversy. It was followed by a refusal of the European Medicine Agency, which does not allow the marketing of drugs solely on biological arguments and raised safety issues, and important US coverage limitations by the Centers for Medicare & Medicaid Services. Two other anti-amyloid immunotherapies showed significant results regarding a clinical outcome in phase II trials, and five drugs are being studied in phase III trials. Lecanemab is currently under examination for an 'Accelerated Approval' in the US, with an expected decision in January 2023. The common feature and novelty of these anti-amyloid immunotherapies, compared to those tested in previous trials of the 2010s, is their ability to induce a high clearance of amyloid load, as measured with positron emission tomography, in the brain of early-stage biomarker-proven AD patients. In the first part of this review, we underlined through a meta-analysis that the pooled data from high-clearance anti-amyloid immunotherapies trials demonstrated a significant but slight clinical effect after 18 months. Still, safety remains an issue with serious and symptomatic amyloid-related imaging abnormalities, which are seldom (∼1 per 200 treated patients) but occur beyond chance. In the second part of this review, we hypothesized that there is a high probability that some phase III trials of high-clearance anti-amyloid immunotherapies in early AD will finally be unarguably positive on clinical outcomes in the next five years with acceptable safety data. This may, in turn, lead to approval by the European Medicine Agency if the risk-benefit profile is deemed favorable. Such approval would be a game-changer in managing AD patients and for the organization of memory clinics in France. We review the possible timeline and scenarios for putative approval in France and make propositions regarding putative use in clinical practice, putative implementation in a real-life setting, and ethical considerations.
Collapse
Affiliation(s)
- N Villain
- AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France; Sorbonne Université, INSERM U1127, CNRS 7225, Institut du Cerveau - ICM, Paris, France.
| | - V Planche
- University Bordeaux, CNRS, IMN, UMR 5293, 33000 Bordeaux, France; Centre Mémoire Ressources Recherches, Pôle de Neurosciences Cliniques, CHU de Bordeaux, 33000 Bordeaux, France
| | - R Levy
- AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France; Sorbonne Université, INSERM U1127, CNRS 7225, Institut du Cerveau - ICM, Paris, France
| |
Collapse
|
17
|
Valyraki N, Maillart E, Pourcher V, Shor N, Tran S, Boudot de la Motte M, Houiller C, Domont F, Morvan E, Touat M, Del Mar Amador M, Aboab J, Mathon B, Hesters A, Vignal-Clermont C, Dehais C, Bonnin S, Lafitte F, Villain N, Varnous S, Gout O, Eloit M, Rodriguez C, Deschamps R. Human pegivirus identified in severe myelitis and optic neuritis in immunocompromised patients: A pathogenic role for a forgotten virus? Rev Neurol (Paris) 2022; 179:361-367. [PMID: 36302709 DOI: 10.1016/j.neurol.2022.06.011] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2022] [Revised: 05/11/2022] [Accepted: 06/08/2022] [Indexed: 11/05/2022]
Abstract
The role of Human pegivirus (HPgV) in patients with encephalitis has been recently questioned. We present cases of 4 patients with similar clinical, biological, and radiological characteristics, including a past history of transplantation with long-term immunosuppression and a progressive course of severe and predominantly myelitis, associated in 3 cases with optic neuropathy causing blindness. Extensive workup was negative but analysis of the CSF by use of pan-microorganism DNA- and RNA-based shotgun metagenomics was positive for HPgV. This case series further supports the hypothesis of HPgV CNS infection and highlights the utility of metagenomic next-generation sequencing of CSF in immunocompromised patients.
Collapse
|
18
|
Sakr FA, Grothe MJ, Cavedo E, Jelistratova I, Habert MO, Dyrba M, Gonzalez-Escamilla G, Bertin H, Locatelli M, Lehericy S, Teipel S, Dubois B, Hampel H, Bakardjian H, Benali H, Bertin H, Bonheur J, Boukadida L, Boukerrou N, Cavedo E, Chiesa P, Colliot O, Dubois B, Dubois M, Epelbaum S, Gagliardi G, Genthon R, Habert MO, Hampel H, Houot M, Kas A, Lamari F, Levy M, Lista S, Metzinger C, Mochel F, Nyasse F, Poisson C, Potier MC, Revillon M, Santos A, Andrade KS, Sole M, Surtee M, de Schotten MT, Vergallo A, Younsi N, Aguilar LF, Babiloni C, Baldacci F, Benda N, Black KL, Bokde ALW, Bonuccelli U, Broich K, Bun RS, Cacciola F, Castrillo J, Cavedo E, Ceravolo R, Chiesa PA, Colliot O, Coman CM, Corvol JC, Cuello AC, Cummings JL, Depypere H, Dubois B, Duggento A, Durrleman S, Escott-Price V, Federoff H, Ferretti MT, Fiandaca M, Frank RA, Garaci F, Genthon R, George N, Giorgi FS, Graziani M, Haberkamp M, Habert MO, Hampel H, Herholz K, Karran E, Kim SH, Koronyo Y, Koronyo-Hamaoui M, Lamari F, Langevin T, Lehéricy S, Lista S, Lorenceau J, Mapstone M, Neri C, Nisticò R, Nyasse-Messene F, O’bryant SE, Perry G, Ritchie C, Rojkova K, Rossi S, Saidi A, Santarnecchi E, Schneider LS, Sporns O, Toschi N, Verdooner SR, Vergallo A, Villain N, Welikovitch LA, Woodcock J, Younesi E. Correction: Applicability of in vivo staging of regional amyloid burden in a cognitively normal cohort with subjective memory complaints: the INSIGHT-preAD study. Alzheimers Res Ther 2022; 14:131. [PMID: 36104713 PMCID: PMC9472399 DOI: 10.1186/s13195-022-01025-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
19
|
Xicota L, Gyorgy B, Grenier-Boley B, Lecoeur A, Fontaine G, Danjou F, Gonzalez JS, Colliot O, Amouyel P, Martin G, Levy M, Villain N, Habert MO, Dubois B, Lambert JC, Potier MC. Association of APOE-Independent Alzheimer Disease Polygenic Risk Score With Brain Amyloid Deposition in Asymptomatic Older Adults. Neurology 2022; 99:e462-e475. [PMID: 35606148 PMCID: PMC9421597 DOI: 10.1212/wnl.0000000000200544] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/28/2021] [Accepted: 03/02/2022] [Indexed: 11/15/2022] Open
Abstract
BACKGROUND AND OBJECTIVES Brain amyloid deposition, a major risk factor for Alzheimer disease (AD), is currently estimated by measuring CSF or plasma amyloid peptide levels or by PET imaging. Assessing genetic risks relating to amyloid deposition before any accumulation has occurred would allow for earlier intervention in persons at increased risk for developing AD. Previous work linking amyloid burden and genetic risk relied almost exclusively on APOE, a major AD genetic risk factor. Here, we ask whether a polygenic risk score (PRS) that incorporates an optimized list of common variants linked to AD and excludes APOE is associated with brain amyloid load in cognitively unimpaired older adults. METHODS We included 291 asymptomatic older participants from the INveStIGation of AlzHeimer's PredicTors (INSIGHT pre-AD) cohort who underwent amyloid imaging, including 83 amyloid-positive (+) participants. We used an Alzheimer's (A) PRS composed of 33 AD risk variants excluding APOE and selected the 17 variants that showed the strongest association with amyloid positivity to define an optimized (oA) PRS. Participants from the Alzheimer's Disease Neuroimaging Initiative (ADNI) study (228 participants, 90 amyloid [+]) were tested as a validation cohort. Finally, 2,300 patients with AD and 6,994 controls from the European Alzheimer's Disease Initiative (EADI) were evaluated. RESULTS A-PRS was not significantly associated with amyloid burden in the INSIGHT or ADNI cohorts with or without correction for the APOE genotype. However, oA-PRS was significantly associated with amyloid status independently of APOE adjustment (INSIGHT odds ratio [OR]: 5.26 [1.71-16.88]; ADNI OR: 3.38 [1.02-11.63]). Of interest, oA-PRS accurately discriminated amyloid (+) and (-) APOE ε4 carriers (INSIGHT OR: 181.6 [7.53-10,674.6]; ADNI OR: 44.94 [3.03-1,277]). A-PRS and oA-PRS showed a significant association with disease status in the EADI cohort (OR: 1.68 [1.53-1.85] and 2.06 [1.73-2.45], respectively). Genes assigned to oA-PRS variants were enriched in ontologies related to β-amyloid metabolism and deposition. DISCUSSION PRSs relying on AD genetic risk factors excluding APOE may improve risk prediction for brain amyloid, allowing stratification of cognitively unimpaired individuals at risk of AD independent of their APOE status.
Collapse
Affiliation(s)
- Laura Xicota
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Beata Gyorgy
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Benjamin Grenier-Boley
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Alexandre Lecoeur
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Gaëlle Fontaine
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Fabrice Danjou
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Jorge Samper Gonzalez
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Olivier Colliot
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Philippe Amouyel
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Garance Martin
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Marcel Levy
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Nicolas Villain
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Marie-Odile Habert
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Bruno Dubois
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Jean-Charles Lambert
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France
| | - Marie-Claude Potier
- From the ICM Paris Brain Institute (L.X., B.G., A.L., G.«F., F.D., J.S.G., O.C., N.V., B.D., M.-C.P.), CNRS UMR7225, INSERM U1127, Sorbonne University, Hôpital de la Pitié-Salpêtrière; Univ. Lille (B.G.-B., P.A., J.-C.L.), Inserm, CHU Lille, Institut Pasteur de Lille, U1167-RID-AGE-Facteurs de risque et déterminants moléculaires des maladies liées au vieillissement; Inria (J.S.G., O.C.), Aramis-Project Team, Paris; Centre d'Acquisition et Traitement des Images (CATI platform) (G.M., M.-O.H.), cati-neuroimaging.com, Paris; Centre des Maladies Cognitives et Comportementales (M.L., M.-O.H., B.D.), IM2A, AP-HP, Sorbonne Université, Hôpital de la Salpêtrière; Department of Neurology (N.V., B.D.), Hôpital Pitié-Salpêtrière, AP-HP Sorbonne Université; Sorbonne Université (M.-O.H.), CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, LIB; and AP-HP (M.-O.H.), Hôpital Pitié-Salpêtrière, Médecine Nucléaire, Paris, France.
| |
Collapse
|
20
|
Villain N. [Therapeutic news in Alzheimer’s disease: soon a disease-modifying therapy?]. Geriatr Psychol Neuropsychiatr Vieil 2022; 20:256-260. [PMID: 35929392 DOI: 10.1684/pnv.2022.1042] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Research on disease-modifying treatments for Alzheimer’s disease has resulted in a series of failures over the past 20 years. However, in the last 4 years, five molecules have shown significant effects in phase II or III trials on clinical endpoints (i.e., slowing of cognitive decline). Among these five molecules, three are anti-amyloid immunotherapies: aducanumab, donanemab, and lecanemab responsible for a significant clearance of cerebral amyloid deposits. These results are still awaiting confirmation in order to put an end to the controversy surrounding the Food and Drug Administration’s decision to give conditional approval to aducanumab, which is considered premature by many specialists. Confirmation is also necessary to assess the benefit (magnitude of the slowing of decline) and risk (edema and cerebral hemorrhage induced by these treatments) balance of these molecules, which appears to be so far questionable after 18 months. Masitinib, a treatment whose probable mechanism of action is neuroinflammation, has also shown positive effects that need to be confirmed. Treatments targeting the tau protein are less advanced but weak signals are emerging from immunotherapies in the moderate stages of the disease (semorinemab). There is renewed hope for patients since it may not be unreasonable that these disease-modifying therapies will be part of the French therapeutic arsenal within the next five years.
Collapse
Affiliation(s)
- Nicolas Villain
- AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer, Paris, France
- Institut du Cerveau – ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| |
Collapse
|
21
|
Villain N. Therapeutic news in Alzheimer's disease: Soon a disease-modifying therapy? Rev Neurol (Paris) 2022; 178:437-440. [PMID: 35489824 DOI: 10.1016/j.neurol.2022.02.456] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 02/28/2022] [Indexed: 11/18/2022]
Abstract
Research on disease-modifying treatments for Alzheimer's disease has resulted in a series of failures over the past 20 years. However, in the last three years, four molecules have shown significant effects on clinical endpoints in phase II or III clinical trials (i.e., slowing of cognitive decline). Among these four molecules, three are anti-amyloid immunotherapies: aducanumab, donanemab, and lecanemab, responsible for a significant clearance of cerebral beta-amyloid deposits. These provisional data are still awaiting confirmation to put an end to the controversy surrounding the 2021 Food and Drug Administration's decision to give conditional approval to aducanumab, which is considered premature by many specialists. Confirmation is also necessary to assess the benefit (magnitude of the slowing of cognitive decline) and risk (edema and cerebral hemorrhage induced by these treatments) balance of these molecules. Masitinib, a treatment whose probable mechanism of action is neuroinflammation, has also shown positive effects that need to be confirmed. Therapies targeting the tau protein are less advanced and have yet to be proven. Patients have renewed hope since it may not be unreasonable that these disease-modifying therapies will be part of the French therapeutic arsenal within the next five years.
Collapse
Affiliation(s)
- N Villain
- AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Département de Neurologie, Institut de la Mémoire et de la Maladie d'Alzheimer, 47-83, boulevard de l'Hôpital, 75651 Paris Cedex 13, France; Institut du Cerveau - ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France.
| |
Collapse
|
22
|
Villain N, Dubois B, Frisoni GB, Rabinovici GD, Sabbagh MN, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert M, Nordberg AK, Blennow K, Galasko DR, Stern Y, Rowe CC, Salloway SP, Schneider LS, Cummings JL, Feldman HH. Clinical diagnosis of Alzheimer’s disease: Recommendations of the International Working Group (IWG). Alzheimers Dement 2021. [DOI: 10.1002/alz.051167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Nicolas Villain
- Institut du Cerveau‐ICM, Sorbonne Université, INSERM U1127, CNRS 7225 Paris France
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
| | - Bruno Dubois
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
- Sorbonne Université, AP‐HP, Hôpital de la Pitié‐Salpêtrière, Boulevard de l'hôpital Paris France
| | - Giovanni B. Frisoni
- Memory Clinic and LANVIE‐Laboratory of Neuroimaging of Aging, University Hospitals and University of Geneva Geneva Switzerland
- University of Geneva Geneva Switzerland
- IRCCS Fatebenefratelli Brescia Italy
| | - Gil D. Rabinovici
- Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco San Francisco CA USA
| | | | - Stefano Cappa
- IRCCS San Giovanni di Dio Fatebenefratelli Brescia Italy
- IUSS Pavia Italy
| | - Alexandre Bejanin
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Stéphanie Bombois
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
- Univ Lille, INSERM, CHU Lille, U1171 ‐ Degenerative and Vascular Cognitive Disorders Lille France
| | - Stéphane Epelbaum
- Institut du Cerveau‐ICM, Sorbonne Université, INSERM U1127, CNRS 7225 Paris France
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
- Inria, Aramis Project‐Team, Inria‐APHP Collaboration Paris France
| | - Marc Teichmann
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
| | - Marie‐Odile Habert
- Institut du Cerveau‐ICM, Sorbonne Université, INSERM U1127, CNRS 7225 Paris France
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Nuclear Medicine Paris France
- Sorbonne Université, CNRS, INSERM, Laboratoire d’Imagerie Biomédicale, LIB Paris France
| | - Agneta K. Nordberg
- Center for Alzheimer Research Karolinska Institutet, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Huddinge Sweden
- Karolinska University Hospital, Theme Aging Stockholm Sweden
| | - Kaj Blennow
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal Sweden
- Institute of Neuroscience and Physiology, Sahlgrenska Academy at the University of Gothenburg Mölndal Sweden
| | - Doug R. Galasko
- Department of Neurosciences, University of California San Diego La Jolla CA USA
| | - Yaakov Stern
- Cognitive Neuroscience Division, Department of Neurology, Columbia University New York NY USA
| | - Christopher C. Rowe
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
| | - Stephen P. Salloway
- Alpert Medical School of Brown University Providence RI USA
- Department of Psychiatry, Alpert Medical School of Brown University Providence RI USA
- Butler Hospital Providence RI USA
| | - Lon S. Schneider
- Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California Los Angeles CA USA
| | - Jeffrey L. Cummings
- Cleveland Clinic Lou Ruvo Center for Brain Health Las Vegas NV USA
- Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV) Las Vegas NV USA
| | - Howard H. Feldman
- Alzheimer's Disease Cooperative Study San Diego CA USA
- University of California San Diego La Jolla CA USA
- Shiley‐Marcos Alzheimer's Disease Research Center La Jolla CA USA
| |
Collapse
|
23
|
Dubois B, Villain N, Frisoni G, Rabinovici GD, Sabbagh MN, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert M, Nordberg AK, Blennow K, Galasko DR, Stern Y, Rowe CC, Salloway SP, Schneider LS, Cummings JL, Feldman H. Recommendations of the International Working Group for the clinical diagnosis of Alzheimer’s disease. Alzheimers Dement 2021. [DOI: 10.1002/alz.057538] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Bruno Dubois
- Institute of Memory and Alzheimer's Disease (IM2A), Department of Neurology, Pitié‐Salpêtrière Hospital, AP‐HP Paris, France Paris France
- Brain and Spine Institute, Salpêtrière's Hospital Paris France
| | - Nicolas Villain
- Institut du Cerveau ‐ ICM, Sorbonne Université, INSERM U1127, CNRS 7225 Paris France
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
| | - Giovanni Frisoni
- Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva Geneva Switzerland
- Memory Clinic, Geneva University Hospitals Geneva Switzerland
| | - Gil D. Rabinovici
- Memory and Aging Center, UCSF Weill Institute for Neurosciences, University of California, San Francisco San Francisco CA USA
| | | | - Stefano Cappa
- IRCCS San Giovanni di Dio Fatebenefratelli Brescia Italy
- IUSS Pavia Italy
| | - Alexandre Bejanin
- Centre of Biomedical Investigation Network for Neurodegenerative Diseases (CIBERNED) Madrid Spain
- Sant Pau Memory Unit, Hospital de la Santa Creu i Sant Pau ‐ Biomedical Research Institute Sant Pau ‐ Universitat Autònoma de Barcelona Barcelona Spain
| | - Stéphanie Bombois
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
| | - Stéphane Epelbaum
- APHP,Sorbonne Universités, Inserm, CNRS, Institut du Cerveau et de la Moelle epinière (ICM), Aramis Project‐Team, Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié‐Salpêtrière Paris France
- Institut du Cerveau et de la Moelle Épinière (ICM) Aramis Lab, INSERM U 1127, CNRS UMR 7225 Paris France
| | - Marc Teichmann
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Neurology Paris France
| | - Marie‐Odile Habert
- AP‐HP Sorbonne Université, Hôpital Pitié‐Salpêtrière, Department of Nuclear Medicine Paris France
- Centre pour l’Acquisition et le Traitement des Images (www.cati‐neuroimaging.com) Paris France
- Sorbonne Université, CNRS, INSERM, Laboratoire d’Imagerie Biomédicale, F‐75013 Paris France
| | - Agneta K. Nordberg
- Center for Alzheimer Research Karolinska Institutet, Division of Clinical Geriatrics, Department of Neurobiology, Care Sciences and Society Huddinge Sweden
- Karolinska University Hospital, Theme Aging Stockholm Sweden
| | - Kaj Blennow
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at University of Gothenburg Mölndal Sweden
- Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital Mölndal Sweden
| | - Doug R. Galasko
- Department of Neurosciences, University of California San Diego La Jolla CA USA
| | - Yaakov Stern
- Columbia University Irving Medical Center New York NY USA
| | - Christopher C. Rowe
- Department of Molecular Imaging and Therapy, Austin Health Melbourne VIC Australia
| | - Stephen P. Salloway
- Department of Psychiatry, Alpert Medical School of Brown University Providence RI USA
- Butler Hospital Providence RI USA
| | - Lon S. Schneider
- Department of Psychiatry and Behavioral Sciences, Keck School of Medicine, University of Southern California Los Angeles CA USA
| | - Jeffrey L. Cummings
- Cleveland Clinic Lou Ruvo Center for Brain Health and UNLV Las Vegas NV USA
- Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas (UNLV) Las Vegas NV USA
| | - Howard Feldman
- Alzheimer's Disease Cooperative Study, University of California San Diego La Jolla CA USA
| |
Collapse
|
24
|
Pujol C, Legrand A, Parodi L, Thomas P, Mochel F, Saracino D, Coarelli G, Croon M, Popovic M, Valet M, Villain N, Elshafie S, Issa M, Zuily S, Renaud M, Marelli-Tosi C, Legendre M, Trimouille A, Kemlin I, Mathieu S, Gleeson JG, Lamari F, Galatolo D, Alkouri R, Tse C, Rodriguez D, Ewenczyk C, Fellmann F, Kuntzer T, Blond E, El Hachimi KH, Darios F, Seyer A, Gazi AD, Giavalisco P, Perin S, Boucher JL, Le Corre L, Santorelli FM, Goizet C, Zaki MS, Picaud S, Mourier A, Steculorum SM, Mignot C, Durr A, Trifunovic A, Stevanin G. Implication of folate deficiency in CYP2U1 loss of function. J Exp Med 2021; 218:212651. [PMID: 34546337 PMCID: PMC8480666 DOI: 10.1084/jem.20210846] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Revised: 07/15/2021] [Accepted: 08/05/2021] [Indexed: 11/24/2022] Open
Abstract
Hereditary spastic paraplegias are heterogeneous neurodegenerative disorders. Understanding of their pathogenic mechanisms remains sparse, and therapeutic options are lacking. We characterized a mouse model lacking the Cyp2u1 gene, loss of which is known to be involved in a complex form of these diseases in humans. We showed that this model partially recapitulated the clinical and biochemical phenotypes of patients. Using electron microscopy, lipidomic, and proteomic studies, we identified vitamin B2 as a substrate of the CYP2U1 enzyme, as well as coenzyme Q, neopterin, and IFN-α levels as putative biomarkers in mice and fluids obtained from the largest series of CYP2U1-mutated patients reported so far. We also confirmed brain calcifications as a potential biomarker in patients. Our results suggest that CYP2U1 deficiency disrupts mitochondrial function and impacts proper neurodevelopment, which could be prevented by folate supplementation in our mouse model, followed by a neurodegenerative process altering multiple neuronal and extraneuronal tissues.
Collapse
Affiliation(s)
- Claire Pujol
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute ICM, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Départements Médico-Universitaires Neuroscience 6, Paris, France.,Pasteur Institute, Centre national de la recherche scientifique UMR 3691, Paris, France
| | - Anne Legrand
- Paris University, Paris Cardiovascular Research Centre, Assistance Publique - Hôpitaux de Paris, Hôpital Européen Georges Pompidou, Centre de Référence des Maladies Vasculaires Rares - Institut national de la santé et de la recherche médicale U97, Paris, France
| | - Livia Parodi
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute ICM, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Départements Médico-Universitaires Neuroscience 6, Paris, France
| | - Priscilla Thomas
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute ICM, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Départements Médico-Universitaires Neuroscience 6, Paris, France.,Pasteur Institute, Centre national de la recherche scientifique UMR 3691, Paris, France
| | - Fanny Mochel
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute ICM, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Départements Médico-Universitaires Neuroscience 6, Paris, France
| | - Dario Saracino
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute ICM, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Départements Médico-Universitaires Neuroscience 6, Paris, France
| | - Giulia Coarelli
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute ICM, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Départements Médico-Universitaires Neuroscience 6, Paris, France
| | - Marijana Croon
- Cologne Excellence Cluster for Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany
| | - Milica Popovic
- Cologne Excellence Cluster for Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany
| | - Manon Valet
- Sorbonne University, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Institut de la Vision, Paris, France
| | - Nicolas Villain
- Sorbonne University, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié-Salpêtrière, Department of Neurology, Paris, France
| | - Shahira Elshafie
- Department of Clinical Pathology, Fayoum University, Fayoum, Egypt
| | - Mahmoud Issa
- Department of Clinical Genetics, Human Genetics and Genome Research Division, National Research Centre, Cairo, Egypt
| | - Stephane Zuily
- University of Lorraine, Institut national de la santé et de la recherche médicale U 1116, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France
| | - Mathilde Renaud
- University of Lorraine, Institut national de la santé et de la recherche médicale U 1256, Centre Hospitalier Régional Universitaire de Nancy, Nancy, France
| | - Cécilia Marelli-Tosi
- Mécanismes Moléculaires dans les Démences Neurodégénératives, University of Montpellier, École pratique des hautes études, Institut national de la santé et de la recherche médicale, Montpellier, France; Expert Center for Neurogenetic Diseases, Centre Hospitalier Universitaire, Montpellier, France
| | - Marine Legendre
- Genetics Department, Centre Hospitalier Universitaire de Bordeaux, University of Bordeaux, Bordeaux, France
| | - Aurélien Trimouille
- Genetics Department, Centre Hospitalier Universitaire de Bordeaux, University of Bordeaux, Bordeaux, France
| | - Isabelle Kemlin
- Pediatric Neurology Department, Assistance Publique - Hôpitaux de Paris, Hôpital Armand Trousseau, Groupe Hôpitaux Universitaires Est Parisien, Paris, France
| | - Sophie Mathieu
- Pediatric Neurology Department, Assistance Publique - Hôpitaux de Paris, Hôpital Armand Trousseau, Groupe Hôpitaux Universitaires Est Parisien, Paris, France
| | - Joseph G Gleeson
- Department of Neurosciences, University of California, San Diego, La Jolla, CA
| | - Foudil Lamari
- Metabolic Biochemistry Department, Pitié-Salpêtrière hospital, Assistance Publique - Hôpitaux de Paris, Sorbonne University, Paris, France
| | - Daniele Galatolo
- Molecular Medicine, Istituto di Ricovero e Cura a Carattere Scientifico Stella Maris, Pisa, Italy
| | - Rana Alkouri
- Metabolic Biochemistry Department, Pitié-Salpêtrière hospital, Assistance Publique - Hôpitaux de Paris, Sorbonne University, Paris, France
| | - Chantal Tse
- Metabolic Biochemistry Department, Pitié-Salpêtrière hospital, Assistance Publique - Hôpitaux de Paris, Sorbonne University, Paris, France
| | - Diana Rodriguez
- Pediatric Neurology Department, Assistance Publique - Hôpitaux de Paris, Hôpital Armand Trousseau, Groupe Hôpitaux Universitaires Est Parisien, Paris, France
| | - Claire Ewenczyk
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute ICM, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Départements Médico-Universitaires Neuroscience 6, Paris, France
| | - Florence Fellmann
- University of Lausanne, Service de Génétique médicale, Lausanne, Switzerland
| | - Thierry Kuntzer
- University of Lausanne, Nerve-Muscle Unit, Department of Clinical Neurosciences, Lausanne, Switzerland
| | - Emilie Blond
- Department of Biochemistry and Molecular Biology, Hospices Civils de Lyon, Pierre Bénite, France
| | - Khalid H El Hachimi
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute ICM, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Départements Médico-Universitaires Neuroscience 6, Paris, France.,Paris Sciences et Lettres Research University, École pratique des hautes études, Neurogenetics Unit, Paris, France
| | - Frédéric Darios
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute ICM, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Départements Médico-Universitaires Neuroscience 6, Paris, France
| | | | - Anastasia D Gazi
- Pasteur Institute, Centre national de la recherche scientifique UMR 3691, Paris, France
| | | | - Silvina Perin
- Max Planck Institute for Biology of Ageing, Cologne, Germany
| | - Jean-Luc Boucher
- Paris Descartes University, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Centre national de la recherche scientifique UMR 8601, Paris, France
| | - Laurent Le Corre
- Paris Descartes University, Laboratoire de Chimie et Biochimie Pharmacologiques et Toxicologiques, Centre national de la recherche scientifique UMR 8601, Paris, France
| | - Filippo M Santorelli
- Molecular Medicine, Istituto di Ricovero e Cura a Carattere Scientifico Stella Maris, Pisa, Italy
| | - Cyril Goizet
- Genetics Department, Centre Hospitalier Universitaire de Bordeaux, University of Bordeaux, Bordeaux, France
| | - Maha S Zaki
- Department of Clinical Genetics, Human Genetics and Genome Research Division, National Research Centre, Cairo, Egypt
| | - Serge Picaud
- Sorbonne University, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Institut de la Vision, Paris, France
| | - Arnaud Mourier
- Bordeaux University, Centre national de la recherche scientifique, Institut de Biochimie et Génétique Cellulaires, UMR 5095, Bordeaux, France
| | - Sophie Marie Steculorum
- Group Neurocircuit and Function, Max Planck Institute for Metabolism Research, Cologne, Germany
| | - Cyril Mignot
- Genetics and Cytogenetics Department, Centre de Référence Déficiences Intellectuelles de Causes Rares, Assistance Publique - Hôpitaux de Paris, Paris, France
| | - Alexandra Durr
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute ICM, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Départements Médico-Universitaires Neuroscience 6, Paris, France
| | - Aleksandra Trifunovic
- Cologne Excellence Cluster for Cellular Stress Responses in Aging-Associated Diseases, University of Cologne, Cologne, Germany
| | - Giovanni Stevanin
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute ICM, Institut national de la santé et de la recherche médicale, Centre national de la recherche scientifique, Assistance Publique - Hôpitaux de Paris, Hôpital de la Pitié Salpêtrière, Départements Médico-Universitaires Neuroscience 6, Paris, France.,Paris Sciences et Lettres Research University, École pratique des hautes études, Neurogenetics Unit, Paris, France
| |
Collapse
|
25
|
Planche V, Villain N. US Food and Drug Administration Approval of Aducanumab-Is Amyloid Load a Valid Surrogate End Point for Alzheimer Disease Clinical Trials? JAMA Neurol 2021; 78:1307-1308. [PMID: 34515750 DOI: 10.1001/jamaneurol.2021.3126] [Citation(s) in RCA: 17] [Impact Index Per Article: 5.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/17/2023]
Affiliation(s)
- Vincent Planche
- University of Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, France.,Centre Mémoire Ressources Recherches, Pôle de Neurosciences Cliniques, CHU de Bordeaux, Bordeaux, France
| | - Nicolas Villain
- AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Department of Neurology, Institute of Memory and Alzheimer's Disease, Paris, France.,Institut du Cerveau - ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| |
Collapse
|
26
|
Villain N, Béra G, Habert MO, Kas A, Aubert J, Jaubert O, Valabregue R, Fernandez-Vidal S, Corvol JC, Mangone G, Lehéricy S, Vidailhet M, Grabli D. Dopamine denervation in the functional territories of the striatum: a new MR and atlas-based 123I-FP-CIT SPECT quantification method. J Neural Transm (Vienna) 2021; 128:1841-1852. [PMID: 34704162 DOI: 10.1007/s00702-021-02434-9] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/22/2021] [Accepted: 10/21/2021] [Indexed: 11/30/2022]
Abstract
Current quantification methods of 123I-FP-CIT SPECT rely on anatomical parcellation of the striatum. We propose here to implement a new method based on MRI segmentation and functional atlas of the basal ganglia (MR-ATLAS) that could provide a reliable quantification within the sensorimotor, associative, and limbic territories of the striatum. Patients with Parkinson's disease (PD), idiopathic rapid eye movement sleep behavioral disorder (iRBD), and healthy controls underwent 123I-FP-CIT SPECT, MRI, motor, and cognitive assessments. SPECT data were corrected for partial volume effects and registered to a functional atlas of the striatum to allow quantification in every functional region of the striatum (nucleus accumbens, limbic, associative, and sensorimotor parts of the striatum). The MR-ATLAS quantification method is proved to be reliable in every territory of the striatum. In addition, good correlations were found between cognitive dysexecutive tests and the binding within the functional (limbic) territories of the striatum using the MR-ATLAS method, slightly better than correlations found using the anatomical quantification method. This new MR-ATLAS method provides a robust and useful tool for studying the dopaminergic system in PD, particularly with respect to cognitive functions. It may also be relevant to further unravel the relationship between dopaminergic denervation and cognitive or behavioral symptoms.
Collapse
Affiliation(s)
- Nicolas Villain
- Department of Neurology, AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France. .,Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France.
| | - G Béra
- Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France.,Department of Nuclear Medicine, AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - M-O Habert
- Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France.,Department of Nuclear Medicine, AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.,Laboratoire d'Imagerie Biomédicale, LIB, Sorbonne Université, CNRS, INSERM, Paris, France
| | - A Kas
- Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France.,Department of Nuclear Medicine, AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France.,Laboratoire d'Imagerie Biomédicale, LIB, Sorbonne Université, CNRS, INSERM, Paris, France
| | - J Aubert
- Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| | - O Jaubert
- Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| | - R Valabregue
- Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| | - S Fernandez-Vidal
- Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| | - J-C Corvol
- Department of Neurology, AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France.,Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| | - G Mangone
- Department of Neurology, AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France.,Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| | - S Lehéricy
- Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France.,Department of Neuroradiology, AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, Paris, France
| | - M Vidailhet
- Department of Neurology, AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France.,Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| | - D Grabli
- Department of Neurology, AP-HP Sorbonne Université, Hôpital Pitié-Salpêtrière, 47-83 boulevard de l'Hôpital, 75651, Paris Cedex 13, France.,Institut du Cerveau, ICM, Sorbonne Université, INSERM U1127, CNRS 7225, Paris, France
| | | |
Collapse
|
27
|
Dubois B, Villain N. Preclinical Alzheimer's or asymptomatic at-risk? J Neurol Sci 2021. [DOI: 10.1016/j.jns.2021.117928] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
28
|
Meira B, Degos B, Corsetti E, Doulazmi M, Berthelot E, Virbel-Fleischman C, Dodet P, Méneret A, Mariani LL, Delorme C, Cormier-Dequaire F, Bendetowicz D, Villain N, Tarrano C, Mantisi L, Letrillart H, Louapre C, McGovern E, Worbe Y, Grabli D, Vidailhet M, Hainque E, Roze E. Long-term effect of apomorphine infusion in advanced Parkinson's disease: a real-life study. NPJ Parkinsons Dis 2021; 7:50. [PMID: 34117268 PMCID: PMC8196159 DOI: 10.1038/s41531-021-00194-7] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 11/09/2020] [Accepted: 04/09/2021] [Indexed: 02/06/2023]
Abstract
Long-term effects of continuous subcutaneous apomorphine infusion (CSAI) on health-related quality of life (HRQoL) and predictors of CSAI discontinuation are poorly known. Data from consecutive advanced Parkinson’s disease patients treated in routine care were retrospectively collected over 24 months after CSAI initiation, with a focus on the 39-item Parkinson’s disease questionnaire (PDQ-39). We determined predictors of CSAI discontinuation and HRQoL improvement using multiple regression analysis. Of the 110 subjects evaluated over a 2-year period, 35% discontinued CSAI. Of those who continued treatment, HRQoL remained stable with a sustained reduction in motor fluctuations. The observed effect on dyskinesias was mild and transient. Of note, patients with preexisting impulse control disorders showed an overall good tolerability. PDQ-39 was the only baseline predictor of HRQoL improvement after 2 years of treatment. The presence of dyskinesias, poorer psychological status, shorter disease duration, male sex, and worse OFF state were predictors of discontinuation. Best candidates for CSAI are patients with: (i) poor baseline HRQoL and (ii) marked motor fluctuations.
Collapse
Affiliation(s)
- Bruna Meira
- Neurology Department, Centro Hospitalar Lisboa Ocidental, Lisbon, Portugal
| | - Bertrand Degos
- Neurology Department, Avicenne Hospital, AP-HP, Sorbonne Paris Nord University, Bobigny, France
| | - Elise Corsetti
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
| | - Mohamed Doulazmi
- Adaptation Biologique et Vieillissement, Institut de Biologie Paris Seine, Sorbonne University, CNRS, Paris, France
| | - Emeline Berthelot
- Neurology Department, Hôpital Zobda Quitman, Fort-de-France, French West Indies, France
| | - Clara Virbel-Fleischman
- Air Liquide SA, Explor Center (Healthcare), Fort-de-France, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - Pauline Dodet
- Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France.,Sleep Disorders (Department "R3S"), Pitié-Salpêtrière Hospital, Paris, France
| | - Aurélie Méneret
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - Louise-Laure Mariani
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - Cécile Delorme
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - Florence Cormier-Dequaire
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - David Bendetowicz
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - Nicolas Villain
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France.,Sorbonne Université, GRC no 21, Alzheimer Precision Medicine, Paris, France
| | - Clément Tarrano
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - Lise Mantisi
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
| | - Hélène Letrillart
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
| | - Céline Louapre
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - Eavan McGovern
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France
| | - Yulia Worbe
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Neurophysiology Department, Saint Antoine Hospital, AP-HP, Paris, France
| | - David Grabli
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - Marie Vidailhet
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - Elodie Hainque
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France.,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France
| | - Emmanuel Roze
- Neurology Department, Pitié-Salpêtrière Hospital, AP-HP, Paris, France. .,Paris Brain Institute, Sorbonne University, UMR S 1127, Inserm U 1127, CNRS UMR 7225, Paris, France.
| |
Collapse
|
29
|
Dubois B, Villain N, Frisoni GB, Rabinovici GD, Sabbagh M, Cappa S, Bejanin A, Bombois S, Epelbaum S, Teichmann M, Habert MO, Nordberg A, Blennow K, Galasko D, Stern Y, Rowe CC, Salloway S, Schneider LS, Cummings JL, Feldman HH. Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group. Lancet Neurol 2021; 20:484-496. [PMID: 33933186 PMCID: PMC8339877 DOI: 10.1016/s1474-4422(21)00066-1] [Citation(s) in RCA: 332] [Impact Index Per Article: 110.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/21/2020] [Revised: 01/21/2021] [Accepted: 02/18/2021] [Indexed: 12/13/2022]
Abstract
In 2018, the US National Institute on Aging and the Alzheimer's Association proposed a purely biological definition of Alzheimer's disease that relies on biomarkers. Although the intended use of this framework was for research purposes, it has engendered debate and challenges regarding its use in everyday clinical practice. For instance, cognitively unimpaired individuals can have biomarker evidence of both amyloid β and tau pathology but will often not develop clinical manifestations in their lifetime. Furthermore, a positive Alzheimer's disease pattern of biomarkers can be observed in other brain diseases in which Alzheimer's disease pathology is present as a comorbidity. In this Personal View, the International Working Group presents what we consider to be the current limitations of biomarkers in the diagnosis of Alzheimer's disease and, on the basis of this evidence, we propose recommendations for how biomarkers should and should not be used for diagnosing Alzheimer's disease in a clinical setting. We recommend that Alzheimer's disease diagnosis be restricted to people who have positive biomarkers together with specific Alzheimer's disease phenotypes, whereas biomarker-positive cognitively unimpaired individuals should be considered only at-risk for progression to Alzheimer's disease.
Collapse
Affiliation(s)
- Bruno Dubois
- Assistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France.
| | - Nicolas Villain
- Assistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France
| | - Giovanni B Frisoni
- Laboratory of Neuroimaging of Aging (LANVIE), University of Geneva, Geneva, Switzerland; Memory Clinic, University Hospital of Geneva, Geneva, Switzerland; Laboratory of Alzheimer's Neuroimaging and Epidemiology (LANE), Saint John of God Clinical Research Centre, Brescia, Italy
| | - Gil D Rabinovici
- Memory and Aging Center, Department of Neurology and Department of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, CA, USA
| | - Marwan Sabbagh
- Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, USA
| | - Stefano Cappa
- University School for Advanced Studies, Pavia, Italy; RCCS Mondino Foundation, Pavia, Italy
| | - Alexandre Bejanin
- Sant Pau Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain; Biomedical Research Institute, Hospital de la Santa Creu i Sant Pau, Universitat Autonoma de Barcelona, Barcelona, Spain; Network Center for Biomedical Research in Neurodegenerative Diseases (CIBERNED), Madrid, Spain
| | - Stéphanie Bombois
- Assistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; INSERM, CHU Lille, U1171 - Degenerative and vascular cognitive disorders, University of Lille, Lille, France
| | - Stéphane Epelbaum
- Assistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France; Inria ARAMIS project team, Inria-APHP collaboratio, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France
| | - Marc Teichmann
- Assistance Publique-Hôpitaux de Paris (AP-HP) Department of Neurology, Sorbonne University, Paris, France
| | - Marie-Odile Habert
- AP-HP Department of Nuclear Medicine, Sorbonne University, Paris, France; CNRS, INSERM, Laboratoire d'Imagerie Biomédicale, Sorbonne University, Paris, France; Institut du Cerveau, Sorbonne University, Paris, France
| | - Agneta Nordberg
- Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Karolinska Institute, Stockholm, Sweden; Theme Aging, The Aging Brain, Karolinska University Hospital, Stockholm, Sweden
| | - Kaj Blennow
- Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy at the University of Gothenburg, Mölndal, Sweden; Clinical Neurochemistry Laboratory, Sahlgrenska University Hospital, Mölndal, Sweden
| | - Douglas Galasko
- Department of Neurosciences, University of California San Diego, La Jolla, CA, USA
| | - Yaakov Stern
- Cognitive Neuroscience Division, Department of Neurology, Columbia University, New York, NY, USA
| | - Christopher C Rowe
- Department of Molecular Imaging and Therapy, Austin Health, The University of Melbourne, Melbourne, VIC, Australia
| | - Stephen Salloway
- Department of Neurology and Department of Psychiatry, Alpert Medical School of Brown University, Providence, RI, USA; Butler Hospital, Providence, RI, USA
| | - Lon S Schneider
- Keck School of Medicine of the University of Southern California, Los Angeles, USA
| | - Jeffrey L Cummings
- Cleveland Clinic, Lou Ruvo Center for Brain Health, Las Vegas, NV, USA; Chambers-Grundy Center for Transformative Neuroscience, Department of Brain Health, School of Integrated Health Sciences, University of Nevada Las Vegas, Las Vegas, NV, USA
| | - Howard H Feldman
- Department of Neurosciences, University of California San Diego, La Jolla, CA, USA; Shiley-Marcos Alzheimer's Disease Research Center, University of California San Diego, La Jolla, CA, USA; Alzheimer Disease Cooperative Study, University of California San Diego, La Jolla, CA, USA
| |
Collapse
|
30
|
Biondetti E, Santin MD, Valabrègue R, Mangone G, Gaurav R, Pyatigorskaya N, Hutchison M, Yahia-Cherif L, Villain N, Habert MO, Arnulf I, Leu-Semenescu S, Dodet P, Vila M, Corvol JC, Vidailhet M, Lehéricy S. The spatiotemporal changes in dopamine, neuromelanin and iron characterizing Parkinson's disease. Brain 2021; 144:3114-3125. [PMID: 33978742 PMCID: PMC8634084 DOI: 10.1093/brain/awab191] [Citation(s) in RCA: 49] [Impact Index Per Article: 16.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2021] [Revised: 04/19/2021] [Accepted: 05/06/2021] [Indexed: 11/13/2022] Open
Abstract
In Parkinson's disease, there is a progressive reduction in striatal dopaminergic function, and loss of neuromelanin-containing dopaminergic neurons and increased iron deposition in the substantia nigra. We tested the hypothesis of a relationship between impairment of the dopaminergic system and changes in the iron metabolism. Based on imaging data of patients with prodromal and early clinical Parkinson's disease, we assessed the spatiotemporal ordering of such changes and relationships in the sensorimotor, associative and limbic territories of the nigrostriatal system. Patients with Parkinson's disease (disease duration < 4 years) or idiopathic REM sleep behaviour disorder (a prodromal form of Parkinson's disease) and healthy controls underwent longitudinal examination (baseline and 2-year follow-up). Neuromelanin and iron sensitive MRI and dopamine transporter single-photon emission tomography were performed to assess nigrostriatal levels of neuromelanin, iron, and dopamine. For all three functional territories of the nigrostriatal system, in the clinically most and least affected hemispheres separately, the following was performed: cross-sectional and longitudinal inter-group difference analysis of striatal dopamine and iron, and nigral neuromelanin and iron; in Parkinson's disease patients, exponential fitting analysis to assess the duration of the prodromal phase and the temporal ordering of changes in dopamine, neuromelanin or iron relative to controls; voxel-wise correlation analysis to investigate concomitant spatial changes in dopamine-iron, dopamine-neuromelanin and neuromelanin-iron in the substantia nigra pars compacta. The temporal ordering of dopaminergic changes followed the known spatial pattern of progression involving first the sensorimotor, then the associative and limbic striatal and nigral regions. Striatal dopaminergic denervation occurred first followed by abnormal iron metabolism and finally neuromelanin changes in the substantia nigra pars compacta, which followed the same spatial and temporal gradient observed in the striatum but shifted in time. In conclusion, dopaminergic striatal dysfunction and cell loss in the substantia nigra pars compacta are interrelated with increased nigral iron content.
Collapse
Affiliation(s)
- Emma Biondetti
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,ICM, Centre de NeuroImagerie de Recherche - CENIR, 75013 Paris, France.,ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), 75013 Paris, France
| | - Mathieu D Santin
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,ICM, Centre de NeuroImagerie de Recherche - CENIR, 75013 Paris, France
| | - Romain Valabrègue
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,ICM, Centre de NeuroImagerie de Recherche - CENIR, 75013 Paris, France
| | - Graziella Mangone
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, Centre d'Investigation Clinique Neurosciences, 75013 Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, 75013 Paris, France
| | - Rahul Gaurav
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,ICM, Centre de NeuroImagerie de Recherche - CENIR, 75013 Paris, France.,ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), 75013 Paris, France
| | - Nadya Pyatigorskaya
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), 75013 Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neuroradiology, 75013 Paris, France
| | | | - Lydia Yahia-Cherif
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,ICM, Centre de NeuroImagerie de Recherche - CENIR, 75013 Paris, France
| | - Nicolas Villain
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, 75013 Paris, France
| | - Marie-Odile Habert
- Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Nuclear Medicine, 75013 Paris, France.,Sorbonne Université, CNRS, INSERM, Laboratoire d'Imagerie Biomédicale - LIB, 75006 Paris, France
| | - Isabelle Arnulf
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), 75013 Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Sleep Disorder Unit, 75013 Paris, France
| | - Smaranda Leu-Semenescu
- Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Sleep Disorder Unit, 75013 Paris, France
| | - Pauline Dodet
- Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Sleep Disorder Unit, 75013 Paris, France
| | - Miquel Vila
- Neurodegenerative Diseases Research Group, Vall d'Hebron Research Institute (VHIR)-Center for Networked Biomedical Research on Neurodegenerative Diseases (CIBERNED)-Department of Biochemistry and Molecular Biology, Autonomous University of Barcelona (UAB)-Catalan Institution for Research and Advanced Studies (ICREA), 08010 Barcelona, Spain
| | - Jean-Christophe Corvol
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, Centre d'Investigation Clinique Neurosciences, 75013 Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, 75013 Paris, France
| | - Marie Vidailhet
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), 75013 Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neurology, 75013 Paris, France
| | - Stéphane Lehéricy
- Sorbonne Université, Institut du Cerveau - Paris Brain Institute - ICM, INSERM, CNRS, 75013 Paris, France.,ICM, Centre de NeuroImagerie de Recherche - CENIR, 75013 Paris, France.,ICM, Team "Movement Investigations and Therapeutics" (MOV'IT), 75013 Paris, France.,Assistance Publique Hôpitaux de Paris, Hôpital Pitié-Salpêtrière, Department of Neuroradiology, 75013 Paris, France
| |
Collapse
|
31
|
Legrand A, Pujol C, Durand CM, Mesnil A, Rubera I, Duranton C, Zuily S, Sousa AB, Renaud M, Boucher JL, Pietrancosta N, Adham S, Orssaud C, Marelli C, Casali C, Ziccardi L, Villain N, Ewenczyk C, Durr A, Mignot C, Stevanin G, Billon C, Hureaux M, Jeunemaitre X, Goizet C, Albuisson J. Pseudoxanthoma elasticum overlaps hereditary spastic paraplegia type 56. J Intern Med 2021; 289:709-725. [PMID: 33107650 DOI: 10.1111/joim.13193] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2020] [Accepted: 09/29/2020] [Indexed: 01/31/2023]
Abstract
PURPOSE Pseudoxanthoma elasticum (PXE) is a recessive disorder involving skin, eyes and arteries, mainly caused by ABCC6 pathogenic variants. However, almost one fifth of patients remain genetically unsolved despite extensive genetic screening of ABCC6, as illustrated in a large French PXE series of 220 cases. We searched for new PXE gene(s) to solve the ABCC6-negative patients. METHODS First, family-based exome sequencing was performed, in one ABCC6-negative PXE patient with additional neurological features, and her relatives. CYP2U1, involved in hereditary spastic paraplegia type 56 (SPG56), was selected based on this complex phenotype, and the presence of two candidate variants. Second, CYP2U1 sequencing was performed in a retrospective series of 46 additional ABCC6-negative PXE probands. Third, six additional SPG56 patients were evaluated for PXE skin and eye phenotype. Additionally, plasma pyrophosphate dosage and functional analyses were performed in some of these patients. RESULTS 6.4% of ABCC6-negative PXE patients (n = 3) harboured biallelic pathogenic variants in CYP2U1. PXE skin lesions with histological confirmation, eye lesions including maculopathy or angioid streaks, and various neurological symptoms were present. CYP2U1 missense variants were confirmed to impair protein function. Plasma pyrophosphate levels were normal. Two SPG56 patients (33%) presented some phenotypic overlap with PXE. CONCLUSION CYP2U1 pathogenic variants are found in unsolved PXE patients with neurological findings, including spastic paraplegia, expanding the SPG56 phenotype and highlighting its overlap with PXE. The pathophysiology of ABCC6 and CYP2U1 should be explored to explain their respective role and potential interaction in ectopic mineralization.
Collapse
Affiliation(s)
- A Legrand
- From the, Université de Paris, PARCC, INSERM, Paris, France.,Centre de Référence des Maladies Vasculaires Rares, AP-HP, Hôpital européen Georges Pompidou, Paris, France
| | - C Pujol
- Sorbonne Université; Inserm, U1127; CNRS, UMR 7225; Institut du Cerveau, Paris, France
| | - C M Durand
- Inserm, U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Univ. Bordeaux; Centre de Référence Neurogénétique, Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France
| | - A Mesnil
- Département de Génétique AP-HP, Hôpital européen Georges Pompidou, Paris, France
| | - I Rubera
- Université Côte d'Azur, CNRS-UMR 7370, Laboratoire de Physiomédecine Moléculaire, LabEx ICST, Nice, France
| | - C Duranton
- Université Côte d'Azur, CNRS-UMR 7370, Laboratoire de Physiomédecine Moléculaire, LabEx ICST, Nice, France
| | - S Zuily
- Université de Lorraine, Inserm UMR_S 1116; CHRU de Nancy, Service de Médecine vasculaire, Centre de Compétences Régional des Maladies Vasculaires Rares, Nancy, France
| | - A B Sousa
- Medical Genetics, Department of Pediatrics, Hospital de Santa Maria, Centro Hospitalar Lisboa Norte, Centro Académico de Medicina de Lisboa, Lisboa, Portugal
| | - M Renaud
- CHRU de Nancy, Service de Neurologie, Nancy, France
| | - J L Boucher
- UMR 8601 CNRS, Université de Paris, Paris, France
| | | | - S Adham
- Centre de Référence des Maladies Vasculaires Rares, AP-HP, Hôpital européen Georges Pompidou, Paris, France.,Université de Paris, Paris, France
| | - C Orssaud
- Unité fonctionnelle d'ophtalmologie, AP-HP, Hôpital Européen Georges Pompidou, Paris, France
| | - C Marelli
- Inserm U1198 MMDN; Gui de Chauliac University Hospital, Department of Neurology, Expert Centre for Neurogenetic Diseases and Adult Mitochondrial and Metabolic Diseases, Montpellier, France
| | - C Casali
- Department of SBMC, Sapienza University Rome, Rome, Italy
| | - L Ziccardi
- IRCCS- Fondazione Bietti, Neurophysiology of Vision and Neuroophthalmology Unit, Rome, Italy
| | - N Villain
- Sorbonne Université; Inserm, U1127; CNRS, UMR 7225; Institut du Cerveau; Sorbonne Université, GRC n° 21, Alzheimer Precision Medicine; AP-HP, Hôpital de la Pitié-Salpêtrière; Département de Neurologie, Institut de la Mémoire et de la maladie d'Alzheimer, Paris, France
| | - C Ewenczyk
- Sorbonne Université; Inserm, U1127; CNRS, UMR 7225; Institut du Cerveau; AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, France
| | - A Durr
- Sorbonne Université; Inserm, U1127; CNRS, UMR 7225; Institut du Cerveau; AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique, Paris, France
| | - C Mignot
- Sorbonne Université; Inserm, U1127; CNRS, UMR 7225; Institut du Cerveau; AP-HP, Hôpital de la Pitié-Salpêtrière, Département de Génétique; Centre de Référence Déficiences Intellectuelles de Causes Rares, Paris, France
| | - G Stevanin
- Sorbonne Université; Inserm, U1127; CNRS, UMR 7225; Institut du Cerveau; PSL research University, Ecole Pratique des Hautes Etudes, Neurogenetics team, Paris, France
| | - C Billon
- From the, Université de Paris, PARCC, INSERM, Paris, France.,Centre de Référence des Maladies Vasculaires Rares, AP-HP, Hôpital européen Georges Pompidou, Paris, France
| | - M Hureaux
- From the, Université de Paris, PARCC, INSERM, Paris, France.,Département de Génétique AP-HP, Hôpital européen Georges Pompidou, Paris, France
| | - X Jeunemaitre
- From the, Université de Paris, PARCC, INSERM, Paris, France.,Centre de Référence des Maladies Vasculaires Rares, AP-HP, Hôpital européen Georges Pompidou, Paris, France
| | - C Goizet
- Inserm, U1211, Laboratoire Maladies Rares: Génétique et Métabolisme, Univ. Bordeaux; Centre de Référence Neurogénétique, Service de Génétique Médicale, CHU Bordeaux, Bordeaux, France
| | - J Albuisson
- From the, Université de Paris, PARCC, INSERM, Paris, France.,Centre de Référence des Maladies Vasculaires Rares, AP-HP, Hôpital européen Georges Pompidou, Paris, France.,Département de Biologie et Pathologie des Tumeurs, Centre Georges François Leclerc, Dijon, France
| |
Collapse
|
32
|
Bombois S, Houot M, Epelbaum S, Villain N, Younsi N, Habert MO, Dubois B. Étude INSIGHT-preAD facteurs de progression vers la maladie d’Alzheimer prodromale à 5 ans de suivi. Rev Neurol (Paris) 2021. [DOI: 10.1016/j.neurol.2021.02.094] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
33
|
McGovern E, Louapre C, Cassereau J, Flamand-Roze C, Corsetti E, Jegatheesan P, Bendetowicz D, Giron C, Dunoyer M, Villain N, Renaud MC, Sauleau P, Michel L, Vérin M, Worbe Y, Falissard B, Roze E. NeuroQ: A neurophobia screening tool assesses how roleplay challenges neurophobia. J Neurol Sci 2021; 421:117320. [PMID: 33518377 DOI: 10.1016/j.jns.2021.117320] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/07/2020] [Revised: 12/20/2020] [Accepted: 01/13/2021] [Indexed: 10/22/2022]
Abstract
BACKGROUND Neurophobia is a chronic disease of medical students and junior doctors. Early detection is needed to facilitate prevention and management as this fear can negatively impact patient care. METHODS We conducted a two-part mono-centric study at the faculty of Medicine, Sorbonne University, in Paris. Part one: a cross-sectional study to validate a newly constructed neurophobia scale, NeuroQ. Part two: a prospective longitudinal study to assess the impact of The Move on student neurophobia using NeuroQ. A population-based sample of second-year medical students of the 2019 and 2020 class of the Faculty of Medicine of Sorbonne University were invited to participate. RESULTS NeuroQ incorporates the main themes of the neurophobia definition and demonstrates uni-dimensionality. Three hundred and ninety-five medical students participated in the study (mean age was 20.0 years, SD: 2.1 years) assessing the effect of The Move teaching on neurophobia. Two hundred and eighty-eight (72.9%) students were female. After the Move teaching the mean NeuroQ score was significantly lower compared to the baseline NeuroQ score (mean [SD] variation, -1.1 [2.6], p < 0.001). There was a 22.3% relative reduction in the number of neurophobic students after The Move teaching. CONCLUSION Our results highlight the utility of NeuroQ in assessing (i) baseline neurophobia and (ii) the impact of pre-clinical educational interventions on neurophobia. Furthermore, we have shown the importance of pre-clinical educational interventions, such as The Move, in tackling neurophobia.
Collapse
Affiliation(s)
- Eavan McGovern
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Neurologie, Paris, France; Sorbonne Université, France; INSERM U1127, CNRS 7225, Institut du Cerveau, Paris, France.
| | - Céline Louapre
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Neurologie, Paris, France; Sorbonne Université, France; INSERM U1127, CNRS 7225, Institut du Cerveau, Paris, France
| | - Julien Cassereau
- Université d'Angers, Faculté de Médecine, Angers, France; Hôpital Universitaire d'Angers, Angers, France
| | | | - Elise Corsetti
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Neurologie, Paris, France
| | | | - David Bendetowicz
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Neurologie, Paris, France; Sorbonne Université, France; INSERM U1127, CNRS 7225, Institut du Cerveau, Paris, France
| | - Camille Giron
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Neurologie, Paris, France; Sorbonne Université, France
| | - Margaux Dunoyer
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Neurologie, Paris, France; Sorbonne Université, France
| | - Nicolas Villain
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Neurologie, Paris, France; Sorbonne Université, France; INSERM U1127, CNRS 7225, Institut du Cerveau, Paris, France
| | | | - Paul Sauleau
- Hôpital Universitaire de Rennes, Département de Neurologie, Rennes, France; Institut des Neurosciences Cliniques de Rennes, équipe EA4712, Rennes, France
| | - Laure Michel
- Hôpital Universitaire de Rennes, Département de Neurologie, Rennes, France; Université Rennes 1, Rennes, France
| | - Marc Vérin
- Hôpital Universitaire de Rennes, Département de Neurologie, Rennes, France; Institut des Neurosciences Cliniques de Rennes, équipe EA4712, Rennes, France; Université Rennes 1, Rennes, France
| | - Yulia Worbe
- Sorbonne Université, France; INSERM U1127, CNRS 7225, Institut du Cerveau, Paris, France; AP-HP, Hôpital Saint Antoine, Service de Neurophysiologie, Paris, France
| | - Bruno Falissard
- Centre de Recherche en Epidémiologie et Santé des Populations, Villejuif, France; Université Paris-Saclay, Faculté de Médecine, Département de Santé Publique, Villejuif, France
| | - Emmanuel Roze
- AP-HP, Hôpital Pitié-Salpêtrière, Département de Neurologie, Paris, France; Sorbonne Université, France; INSERM U1127, CNRS 7225, Institut du Cerveau, Paris, France
| |
Collapse
|
34
|
Bailly L, Villain N, Houot M, Hourregue C, Paquet C, Leroy M, Lebouvier T, Dubois B, Epelbaum S. In‐vivo characterization of progressive amnestic syndrome due to suspected neurodegenerative non‐Alzheimer’s disease. Alzheimers Dement 2020. [DOI: 10.1002/alz.039587] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/09/2022]
Affiliation(s)
- Laurent Bailly
- Institute of Memory and Alzheimer Disease Pitie‐Salpetriere University Hospital Paris France
| | - Nicolas Villain
- Institute of Memory and Alzheimer Disease Pitie‐Salpetriere University Hospital Paris France
- Institut du Cerveau et de la Moelle (ICM) Paris France
| | - Marion Houot
- Institute of Memory and Alzheimer Disease Pitie‐Salpetriere University Hospital Paris France
- Institut du Cerveau et de la Moelle (ICM) Paris France
| | - Claire Hourregue
- Cognitive Neurology Center, Hôpital Lariboisière‐Fernand Widal APHP Paris France
| | - Claire Paquet
- Cognitive Neurology Center, Hôpital Lariboisière‐Fernand Widal APHP Paris France
| | - Melanie Leroy
- Univ. Lille, INSERM, CHU‐Lille, Lille Neuroscience & Cognition F‐59000 Lille France
| | - Thibaud Lebouvier
- Univ. Lille, INSERM, CHU‐Lille, Lille Neuroscience & Cognition F‐59000 Lille France
| | - Bruno Dubois
- Institute of Memory and Alzheimer Disease Pitie‐Salpetriere University Hospital Paris France
- Institut du Cerveau et de la Moelle (ICM) Paris France
| | - Stéphane Epelbaum
- Institute of Memory and Alzheimer Disease Pitie‐Salpetriere University Hospital Paris France
- Institut du Cerveau et de la Moelle (ICM) Paris France
| |
Collapse
|
35
|
|
36
|
Dubois B, Bombois S, Villain N, Teichmann M, Epelbaum S, Migliaccio R, Genthon R, Verrat B, Lesoil C, Levy M, Le Ber I, Levy R. [Toward a preventive management Alzheimer's disease]. Bull Acad Natl Med 2020; 204:583-588. [PMID: 32322104 PMCID: PMC7172758 DOI: 10.1016/j.banm.2020.04.012] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Subscribe] [Scholar Register] [Received: 02/18/2020] [Accepted: 04/10/2020] [Indexed: 11/03/2022]
Abstract
Les démences et la maladie d’Alzheimer (MA), en particulier, vont devenir de plus en plus un enjeu de santé publique. Trois données importantes peuvent cependant modifier le poids de ces pathologies : (1) de simples mesures d’hygiène de vie (contrôle de facteurs de risque vasculaire, activité physique et stimulation cognitive) instaurées chez les jeunes adultes ont un impact sur un déclin cognitif ultérieur ; (2) chez des sujets âgés à risque, ces mêmes dispositions retardent l’entrée dans la maladie et (3) enfin et pour la première fois, un anticorps anti-amyloïde aurait montré un effet significatif sur l’évolution de la MA chez des patients au stade débutant. Il ressort de ces travaux qu’il faut se préparer à reconsidérer la stratégie de prise en charge des troubles cognitifs, qu’ils soient mineurs ou majeurs, et de la MA en particulier. L’entrée des patients dans le parcours de soins reste aujourd’hui trop tardive. La solution est d’agir plus précocement, voire de façon préventive. Il faut développer une offre de soins adaptée à cette situation nouvelle afin d’agir sur la maladie le plus tôt possible, fondée sur : 1) des algorithmes prédictifs pour déterminer chez les sujets sans symptômes spécifiques ceux qui seront à risque de développer une pathologie dégénérative; ces algorithmes devront être mis au point à partir de données démographiques, familiales, cognitives, génomiques et biologiques, comme celles recueillies dans le projet « Santé-Cerveau » développé en partenariat avec l’ARS et les médecins généralistes ; 2) le renforcement des activités de prévention dans les 450 centres mémoire de proximité disponibles en France et les 26 CM2R et 3) la transformation de quelques-uns de ces centres experts en « cliniques de prévention de la démence » pour tester les mesures de prévention, initier des programmes d’éducation thérapeutique multidomaine et les valider, communiquer sur le risque, répondre à la demande de sujets inquiets et déterminer, chez ceux-ci, à l’aide des algorithmes, le niveau de risque qu’ils ont de déclarer une MA dans les mois et années qui viennent, en tenant compte de la compétition entre les risques. On peut ainsi se préparer à faire bénéficier précocement les uns et les autres des traitements pharmacologiques susceptibles d’exister.
Collapse
Affiliation(s)
- B Dubois
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Sorbonne-Université, Paris, France.,Centre national de référence « maladie Alzheimer Jeune ».,Centre national de référence « démences rares et précoces »
| | - S Bombois
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Centre national de référence « maladie Alzheimer Jeune »
| | - N Villain
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Sorbonne-Université, Paris, France
| | - M Teichmann
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Centre national de référence « démences rares et précoces »
| | - S Epelbaum
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Centre national de référence « maladie Alzheimer Jeune »
| | - R Migliaccio
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France
| | - R Genthon
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - B Verrat
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - C Lesoil
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - M Levy
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - I Le Ber
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Centre national de référence « démences rares et précoces »
| | - R Levy
- Service des maladies cognitives et comportementales, Institut de la mémoire et de la maladie d'Alzheimer (IM2A), hôpital de la Salpêtrière, AP-PH, 47, boulevard de l'Hôpital, 75013 Paris, France.,Institut du cerveau et de la moelle épinière (ICM), hôpital La Salpêtrière, 75013 Paris, France.,Sorbonne-Université, Paris, France.,Centre national de référence « démences rares et précoces »
| |
Collapse
|
37
|
Langet H, Bonopera M, De Craene M, Popoff A, Denis E, Pizaine G, Dormoy L, Talgorn E, Hodzic A, Villain N, Allain P, Saloux E. 541 Turning novices into experts: can artificial intelligence transform echocardiography training? Eur Heart J Cardiovasc Imaging 2020. [DOI: 10.1093/ehjci/jez319.275] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Funding Acknowledgements
Philips
BACKGROUND
Developing new training tools for TransThoracic Echocardiography (TTE) is more important than ever, as the use of ultrasound expands with the advent of mobile devices, both reducing costs and increasing the number of sites and operators. Two major challenges are the lack of experts to meet the growing demand for training and the risk of unnecessary examinations and misdiagnosis by users who lack proper training.
PURPOSE
To evaluate Artificial Intelligence (AI)-assisted TTE for assessing and improving novices" echocardiography skills.
METHODS
AI-assisted TTE relies on real-time analysis of the ultrasound stream by AI algorithms (e.g. for automated view recognition) to provide adaptive feedback to the user. It was compared to standard TTE in a prospective study including 40 medical students with no prior ultrasound experience ("novices") and 40 healthy volunteers of varying echogenicity. Novices received a standardized 10-minute presentation of the basic machine controls and requirements of an apical 4-chamber (AP4) acquisition. They were then asked to perform three consecutive AP4 acquisitions on a randomly assigned healthy volunteer: 1) "initial" standard TTE, 2) AI-assisted TTE and 3) "repetition" standard TTE, with a maximum of 3 minutes per acquisition. Additionally, for reference purposes, an AP4 acquisition was performed by an expert. Both the performance over time and the final acquisition performance were assessed by an AI-based AP4 quality score and expressed relatively to the reference score. The suitability for clinical use was assessed by an expert on a 0-3 semi-quantitative scale.
RESULTS
Kaplan-Meier analysis of the probability to match reference performance over time (see left part in figure below) validated the positive and significant contribution of AI-assisted TTE wrt initial TTE (median time = 16.1s vs. 45.7s, p = 0.026). There was also a positive, though non-significant, contribution wrt repetition TTE (median time = 25.7s, p = 0.20), while the difference between standard TTEs was non-significant (p = 0.24). A majority of novices (70%, resp. 72.5%) improved their final acquisition with AI-assisted TTE wrt initial TTE, resp. repetition TTE. The final performance gain (81.7 ± 29.7% vs. 60.8 ± 40.4%, resp. 70.4 ± 33.9%, see right part in figure below) was shown to be significant by Wilcoxon matched-pair signed-rank test (p < 0.001, resp. p = 0.003). There was no significant difference between standard TTEs (p = 0.34). AI-assisted TTE was also associated with improved suitability for clinical use (2.53 ± 0.79 vs. 2.00 ± 1.03, resp. 2.08 ± 0.98). Among these acquisitions, 50% were found fully suitable for clinical use (vs. 22.5%, resp. 27.5%).
CONCLUSION
AI-assisted TTE can assess and improve novices" echocardiography skills. Developing and embedding AI-assistance in ultrasound devices could be a cost-effective way to support the training of novices and key to acquisition standardization.
Abstract 541 Figure.
Collapse
Affiliation(s)
- H Langet
- Philips, Clinical Research Board, Suresnes, France
| | - M Bonopera
- University Hospital of Caen, Caen, France
| | - M De Craene
- Philips Research, Medical Imaging (Medisys), Suresnes, France
| | - A Popoff
- Philips Research, Medical Imaging (Medisys), Suresnes, France
| | - E Denis
- Philips Research, Medical Imaging (Medisys), Suresnes, France
| | - G Pizaine
- Philips Research, Medical Imaging (Medisys), Suresnes, France
| | - L Dormoy
- University Hospital of Caen, Caen, France
| | - E Talgorn
- Philips Design, Eindhoven, Netherlands (The)
| | - A Hodzic
- University Hospital of Caen, Caen, France
| | - N Villain
- Philips Research, Medical Imaging (Medisys), Suresnes, France
| | - P Allain
- Philips Research, Medical Imaging (Medisys), Suresnes, France
| | - E Saloux
- University Hospital of Caen, Caen, France
| |
Collapse
|
38
|
Couteaux V, Si-Mohamed S, Renard-Penna R, Nempont O, Lefevre T, Popoff A, Pizaine G, Villain N, Bloch I, Behr J, Bellin MF, Roy C, Rouvière O, Montagne S, Lassau N, Boussel L. Kidney cortex segmentation in 2D CT with U-Nets ensemble aggregation. Diagn Interv Imaging 2019; 100:211-217. [DOI: 10.1016/j.diii.2019.03.001] [Citation(s) in RCA: 15] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 03/06/2019] [Accepted: 03/06/2019] [Indexed: 10/27/2022]
|
39
|
Abstract
AbstractAlzheimer's disease (AD) is the commonest neurodegenerative disease and the most frequent cause of dementia. It affects 30 million people worldwide. Current research criteria focus on biomarkers' status for amyloid and tau using positron emission tomography and cerebrospinal fluid analysis, independent of clinical status. Current epidemiological data, which mostly rely on biomarker-undetermined AD cases, have highlighted ApoE4 and age as the main risk factors. Rare autosomal dominant mutations also account for a small fraction of early-onset AD. The main clinical phenotype at presentation is the amnestic phenotype targeting episodic memory. This is followed by rarer phenotypes such as posterior cortical atrophy, logopenic variant of primary progressive aphasia, frontal variant AD, corticobasal syndrome, and other even rarer presentations mimicking language variants of frontotemporal dementia. Main differential diagnoses include hippocampal sclerosis with TDP-43, primary age-related tauopathy, argyrophilic grain disease, frontotemporal lobar degeneration, Lewy body disease, chronic traumatic encephalopathy as well as nondegenerative disorders such as cerebrovascular disease, chronic alcohol consumption, limbic encephalitis, medial temporal lobe epilepsy, and others. Co-occurrence of AD pathology with other neurodegenerative and vascular diseases is common and increases with age. This presents a challenge in current clinical practice due to a lack of reliable biomarkers for non-AD neurodegenerative diseases.
Collapse
Affiliation(s)
- Nicolas Villain
- Alzheimer Precision Medicine, Sorbonne Université, Paris, France
- Department of Neurology, Institute of Memory and Alzheimer's Disease, Assistance Publique - Hopitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
- Institut du Cerveau et de la Moëlle Epinière, Paris, France
| | - Bruno Dubois
- Department of Neurology, Institute of Memory and Alzheimer's Disease, Assistance Publique - Hopitaux de Paris, Pitié-Salpêtrière Hospital, Paris, France
- Institut du Cerveau et de la Moëlle Epinière, Paris, France
| |
Collapse
|
40
|
Couteaux V, Si-Mohamed S, Nempont O, Lefevre T, Popoff A, Pizaine G, Villain N, Bloch I, Cotten A, Boussel L. Automatic knee meniscus tear detection and orientation classification with Mask-RCNN. Diagn Interv Imaging 2019; 100:235-242. [PMID: 30910620 DOI: 10.1016/j.diii.2019.03.002] [Citation(s) in RCA: 50] [Impact Index Per Article: 10.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/22/2019] [Revised: 03/06/2019] [Accepted: 03/06/2019] [Indexed: 10/27/2022]
Abstract
PURPOSE This work presents our contribution to a data challenge organized by the French Radiology Society during the Journées Francophones de Radiologie in October 2018. This challenge consisted in classifying MR images of the knee with respect to the presence of tears in the knee menisci, on meniscal tear location, and meniscal tear orientation. MATERIALS AND METHODS We trained a mask region-based convolutional neural network (R-CNN) to explicitly localize normal and torn menisci, made it more robust with ensemble aggregation, and cascaded it into a shallow ConvNet to classify the orientation of the tear. RESULTS Our approach predicted accurately tears in the database provided for the challenge. This strategy yielded a weighted AUC score of 0.906 for all three tasks, ranking first in this challenge. CONCLUSION The extension of the database or the use of 3D data could contribute to further improve the performances especially for non-typical cases of extensively damaged menisci or multiple tears.
Collapse
Affiliation(s)
- V Couteaux
- Philips Research France, 33, rue de Verdun, 92150 Suresnes, France; LTCI, Télécom ParisTech, université Paris-Saclay, 46, rue Barrault, 75013 Paris, France.
| | - S Si-Mohamed
- Inserm U1206, INSA-Lyon, Claude-Bernard-Lyon 1 University, CREATIS, CNRS UMR 5220, 69100 Villeurbanne, France; Department of Radiology, hospices civils de Lyon, 69002 Lyon, France
| | - O Nempont
- Philips Research France, 33, rue de Verdun, 92150 Suresnes, France
| | - T Lefevre
- Philips Research France, 33, rue de Verdun, 92150 Suresnes, France
| | - A Popoff
- Philips Research France, 33, rue de Verdun, 92150 Suresnes, France
| | - G Pizaine
- Philips Research France, 33, rue de Verdun, 92150 Suresnes, France
| | - N Villain
- Philips Research France, 33, rue de Verdun, 92150 Suresnes, France
| | - I Bloch
- LTCI, Télécom ParisTech, université Paris-Saclay, 46, rue Barrault, 75013 Paris, France
| | - A Cotten
- Department of Musculoskeletal Radiology, CHRU de Lille, 59000 Lille, France
| | - L Boussel
- Inserm U1206, INSA-Lyon, Claude-Bernard-Lyon 1 University, CREATIS, CNRS UMR 5220, 69100 Villeurbanne, France; Department of Radiology, hospices civils de Lyon, 69002 Lyon, France
| |
Collapse
|
41
|
El Nawar R, Villain N, Baud JM, De Malherbe M, Pico F. Carotid contrast-enhanced ultrasonography and multimodal imaging in a case of TIPIC syndrome. Rev Neurol (Paris) 2018; 174:304-307. [PMID: 29673574 DOI: 10.1016/j.neurol.2018.01.367] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/20/2017] [Revised: 12/28/2017] [Accepted: 01/12/2018] [Indexed: 11/19/2022]
Abstract
Transient perivascular inflammation of the carotid artery (TIPIC) syndrome, previously referred to as 'carotidynia', is an unclassified clinicoradiological entity associating atypical acute neck pain, eccentric perivascular infiltration on imaging and improvement of symptoms either spontaneously or with anti-inflammatory treatment. This case report presents a patient with TIPIC syndrome who underwent five different types of imaging modality, including contrast-enhanced ultrasonography (CEUS) of the carotids, and describes the CEUS appearances of TIPIC syndrome.
Collapse
Affiliation(s)
- R El Nawar
- Department of Neurology and Stroke Center, Centre Hospitalier de Versailles, Versailles, France; Department of Neurology, Gilbert and Rose-Marie Chagoury School of Medicine, Lebanese American University Medical Center, Beirut, Lebanon.
| | - N Villain
- Department of Neurology and Stroke Center, Centre Hospitalier de Versailles, Versailles, France
| | - J-M Baud
- Angiology and Ultrasound Unit, Centre Hospitalier de Versailles, Versailles, France
| | - M De Malherbe
- Radiology Department, Centre Hospitalier de Versailles, Versailles, France
| | - F Pico
- Department of Neurology and Stroke Center, Centre Hospitalier de Versailles, Versailles, France; Université Versailles Saint-Quentin en Yvelines et Paris Saclay, France
| |
Collapse
|
42
|
Hampel H, Toschi N, Babiloni C, Baldacci F, Black KL, Bokde AL, Bun RS, Cacciola F, Cavedo E, Chiesa PA, Colliot O, Coman CM, Dubois B, Duggento A, Durrleman S, Ferretti MT, George N, Genthon R, Habert MO, Herholz K, Koronyo Y, Koronyo-Hamaoui M, Lamari F, Langevin T, Lehéricy S, Lorenceau J, Neri C, Nisticò R, Nyasse-Messene F, Ritchie C, Rossi S, Santarnecchi E, Sporns O, Verdooner SR, Vergallo A, Villain N, Younesi E, Garaci F, Lista S. Revolution of Alzheimer Precision Neurology. Passageway of Systems Biology and Neurophysiology. J Alzheimers Dis 2018; 64:S47-S105. [PMID: 29562524 PMCID: PMC6008221 DOI: 10.3233/jad-179932] [Citation(s) in RCA: 95] [Impact Index Per Article: 15.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/18/2023]
Abstract
The Precision Neurology development process implements systems theory with system biology and neurophysiology in a parallel, bidirectional research path: a combined hypothesis-driven investigation of systems dysfunction within distinct molecular, cellular, and large-scale neural network systems in both animal models as well as through tests for the usefulness of these candidate dynamic systems biomarkers in different diseases and subgroups at different stages of pathophysiological progression. This translational research path is paralleled by an "omics"-based, hypothesis-free, exploratory research pathway, which will collect multimodal data from progressing asymptomatic, preclinical, and clinical neurodegenerative disease (ND) populations, within the wide continuous biological and clinical spectrum of ND, applying high-throughput and high-content technologies combined with powerful computational and statistical modeling tools, aimed at identifying novel dysfunctional systems and predictive marker signatures associated with ND. The goals are to identify common biological denominators or differentiating classifiers across the continuum of ND during detectable stages of pathophysiological progression, characterize systems-based intermediate endophenotypes, validate multi-modal novel diagnostic systems biomarkers, and advance clinical intervention trial designs by utilizing systems-based intermediate endophenotypes and candidate surrogate markers. Achieving these goals is key to the ultimate development of early and effective individualized treatment of ND, such as Alzheimer's disease. The Alzheimer Precision Medicine Initiative (APMI) and cohort program (APMI-CP), as well as the Paris based core of the Sorbonne University Clinical Research Group "Alzheimer Precision Medicine" (GRC-APM) were recently launched to facilitate the passageway from conventional clinical diagnostic and drug development toward breakthrough innovation based on the investigation of the comprehensive biological nature of aging individuals. The APMI movement is gaining momentum to systematically apply both systems neurophysiology and systems biology in exploratory translational neuroscience research on ND.
Collapse
Affiliation(s)
- Harald Hampel
- AXA Research Fund & Sorbonne Université Chair, Paris, France
- Sorbonne Université, AP-HP, GRC n° 21, Alzheimer Precision Medicine (APM), Hôpital de la Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
- Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l’hôpital, F-75013, Paris, France
- Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié-Salpêtrière, AP-HP, Boulevard de l’hôpital, F-75013, Paris, France
| | - Nicola Toschi
- Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy
- Department of Radiology, “Athinoula A. Martinos” Center for Biomedical Imaging, Boston, MA, USA
- Harvard Medical School, Boston, MA, USA
| | - Claudio Babiloni
- Department of Physiology and Pharmacology “Vittorio Erspamer”, University of Rome “La Sapienza”, Rome, Italy
- Institute for Research and Medical Care, IRCCS “San Raffaele Pisana”, Rome, Italy
| | - Filippo Baldacci
- AXA Research Fund & Sorbonne Université Chair, Paris, France
- Sorbonne Université, AP-HP, GRC n° 21, Alzheimer Precision Medicine (APM), Hôpital de la Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
- Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l’hôpital, F-75013, Paris, France
- Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié-Salpêtrière, AP-HP, Boulevard de l’hôpital, F-75013, Paris, France
- Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy
| | - Keith L. Black
- Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Arun L.W. Bokde
- Discipline of Psychiatry, School of Medicine and Trinity College Institute of Neuroscience (TCIN), Trinity College Dublin, Dublin, Ireland
| | - René S. Bun
- AXA Research Fund & Sorbonne Université Chair, Paris, France
- Sorbonne Université, AP-HP, GRC n° 21, Alzheimer Precision Medicine (APM), Hôpital de la Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
- Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l’hôpital, F-75013, Paris, France
- Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié-Salpêtrière, AP-HP, Boulevard de l’hôpital, F-75013, Paris, France
| | - Francesco Cacciola
- Unit of Neurosurgery, Azienda Ospedaliera Universitaria Senese, Siena, Italy
| | - Enrica Cavedo
- AXA Research Fund & Sorbonne Université Chair, Paris, France
- Sorbonne Université, AP-HP, GRC n° 21, Alzheimer Precision Medicine (APM), Hôpital de la Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
- Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l’hôpital, F-75013, Paris, France
- Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié-Salpêtrière, AP-HP, Boulevard de l’hôpital, F-75013, Paris, France
- IRCCS “San Giovanni di Dio-Fatebenefratelli”, Brescia, Italy
| | - Patrizia A. Chiesa
- AXA Research Fund & Sorbonne Université Chair, Paris, France
- Sorbonne Université, AP-HP, GRC n° 21, Alzheimer Precision Medicine (APM), Hôpital de la Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
- Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l’hôpital, F-75013, Paris, France
- Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié-Salpêtrière, AP-HP, Boulevard de l’hôpital, F-75013, Paris, France
| | - Olivier Colliot
- Inserm, U1127, Paris, France; CNRS, UMR 7225 ICM, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France; Institut du Cerveau et de la Moelle Épinière (ICM) Paris, France; Inria, Aramis project-team, Centre de Recherche de Paris, France; Department of Neuroradiology, AP-HP, Hôpital de la Pitié-Salpêtrière, Paris, France; Department of Neurology, AP-HP, Hôpital de la Pitié-Salpêtrière, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Paris, France
| | - Cristina-Maria Coman
- AXA Research Fund & Sorbonne Université Chair, Paris, France
- Sorbonne Université, AP-HP, GRC n° 21, Alzheimer Precision Medicine (APM), Hôpital de la Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
- Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l’hôpital, F-75013, Paris, France
- Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié-Salpêtrière, AP-HP, Boulevard de l’hôpital, F-75013, Paris, France
| | - Bruno Dubois
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle Épinière (ICM), Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
| | - Andrea Duggento
- Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy
| | - Stanley Durrleman
- Inserm, U1127, Paris, France; CNRS, UMR 7225 ICM, Paris, France; Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127, Paris, France; Institut du Cerveau et de la Moelle Épinière (ICM) Paris, France; Inria, Aramis project-team, Centre de Recherche de Paris, France
| | - Maria-Teresa Ferretti
- IREM, Institute for Regenerative Medicine, University of Zurich, Zürich, Switzerland
- ZNZ Neuroscience Center Zurich, Zürich, Switzerland
| | - Nathalie George
- Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, Institut du Cerveau et de la Moelle Épinière, ICM, Ecole Normale Supérieure, ENS, Centre MEG-EEG, F-75013, Paris, France
| | - Remy Genthon
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle Épinière (ICM), Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
| | - Marie-Odile Habert
- Département de Médecine Nucléaire, Hôpital de la Pitié-Salpêtrière, AP-HP, Paris, France
- Laboratoire d’Imagerie Biomédicale, Sorbonne Universités, UPMC Univ Paris 06, Inserm U 1146, CNRS UMR 7371, Paris, France
| | - Karl Herholz
- Division of Neuroscience and Experimental Psychology, University of Manchester, Manchester, UK
- Division of Informatics, Imaging and Data Sciences, University of Manchester, Wolfson Molecular Imaging Centre, Manchester, UK
| | - Yosef Koronyo
- Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Maya Koronyo-Hamaoui
- Department of Neurosurgery, Maxine Dunitz Neurosurgical Research Institute, Cedars-Sinai Medical Center, Los Angeles, California, USA
- Department of Biomedical Sciences, Cedars-Sinai Medical Center, Los Angeles, California, USA
| | - Foudil Lamari
- AP-HP, UF Biochimie des Maladies Neuro-métaboliques, Service de Biochimie Métabolique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France
| | | | - Stéphane Lehéricy
- Centre de NeuroImagerie de Recherche - CENIR, Institut du Cerveau et de la Moelle Épinière - ICM, F-75013, Paris, France
- Sorbonne Universités, UPMC Univ Paris 06 UMR S 1127, Inserm U 1127, CNRS UMR 7225, ICM, F-75013, Paris, France
| | - Jean Lorenceau
- Institut de la Vision, INSERM, Sorbonne Universités, UPMC Univ Paris 06, UMR_S968, CNRS UMR7210, Paris, France
| | - Christian Neri
- Sorbonne Universités, Université Pierre et Marie Curie (UPMC) Paris 06, CNRS UMR 8256, Institut de Biologie Paris-Seine (IBPS), Place Jussieu, F-75005, Paris, France
| | - Robert Nisticò
- Department of Biology, University of Rome “Tor Vergata” & Pharmacology of Synaptic Disease Lab, European Brain Research Institute (E.B.R.I.), Rome, Italy
| | - Francis Nyasse-Messene
- Sorbonne Université, Inserm, CNRS, Institut du Cerveau et de la Moelle Épinière (ICM), Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Hôpital Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
| | - Craig Ritchie
- Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh, UK
| | - Simone Rossi
- Department of Medicine, Surgery and Neurosciences, Unit of Neurology and Clinical Neurophysiology, Brain Investigation & Neuromodulation Lab. (Si-BIN Lab.), University of Siena, Siena, Italy
- Department of Medicine, Surgery and Neurosciences, Section of Human Physiology University of Siena, Siena, Italy
| | - Emiliano Santarnecchi
- Department of Medicine, Surgery and Neurosciences, Unit of Neurology and Clinical Neurophysiology, Brain Investigation & Neuromodulation Lab. (Si-BIN Lab.), University of Siena, Siena, Italy
- Berenson-Allen Center for Noninvasive Brain Stimulation, Department of Neurology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA
| | - Olaf Sporns
- Department of Psychological and Brain Sciences, Indiana University, Bloomington, IN, USA
- IU Network Science Institute, Indiana University, Bloomington, IN, USA
| | | | - Andrea Vergallo
- AXA Research Fund & Sorbonne Université Chair, Paris, France
- Sorbonne Université, AP-HP, GRC n° 21, Alzheimer Precision Medicine (APM), Hôpital de la Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
- Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l’hôpital, F-75013, Paris, France
- Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié-Salpêtrière, AP-HP, Boulevard de l’hôpital, F-75013, Paris, France
| | - Nicolas Villain
- Sorbonne Université, AP-HP, GRC n° 21, Alzheimer Precision Medicine (APM), Hôpital de la Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
- Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l’hôpital, F-75013, Paris, France
- Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié-Salpêtrière, AP-HP, Boulevard de l’hôpital, F-75013, Paris, France
| | | | - Francesco Garaci
- Department of Biomedicine and Prevention, University of Rome “Tor Vergata”, Rome, Italy
- Casa di Cura “San Raffaele Cassino”, Cassino, Italy
| | - Simone Lista
- AXA Research Fund & Sorbonne Université Chair, Paris, France
- Sorbonne Université, AP-HP, GRC n° 21, Alzheimer Precision Medicine (APM), Hôpital de la Pitié-Salpêtrière, Boulevard de l’hôpital, F-75013, Paris, France
- Institut du Cerveau et de la Moelle Épinière (ICM), INSERM U 1127, CNRS UMR 7225, Boulevard de l’hôpital, F-75013, Paris, France
- Institut de la Mémoire et de la Maladie d’Alzheimer (IM2A), Département de Neurologie, Hôpital de la Pitié-Salpêtrière, AP-HP, Boulevard de l’hôpital, F-75013, Paris, France
| |
Collapse
|
43
|
Villain N, Mesrati F, Naccache L, Marie V, Roze E, Bertrand D, Garcin B. Caractéristiques cliniques et démographiques des patients ayant un trouble moteur fonctionnel. Rev Neurol (Paris) 2017. [DOI: 10.1016/j.neurol.2017.01.346] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
|
44
|
Gaubert M, Villain N, Landeau B, Mézenge F, Egret S, Perrotin A, Belliard S, de La Sayette V, Eustache F, Desgranges B, Chételat G, Rauchs G. Neural Correlates of Self-Reference Effect in Early Alzheimer’s Disease. J Alzheimers Dis 2017; 56:717-731. [DOI: 10.3233/jad-160561] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Affiliation(s)
- Malo Gaubert
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- UMR-S1077, Caen University Hospital, Caen, France
| | - Nicolas Villain
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- UMR-S1077, Caen University Hospital, Caen, France
| | - Brigitte Landeau
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- UMR-S1077, Caen University Hospital, Caen, France
| | - Florence Mézenge
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- UMR-S1077, Caen University Hospital, Caen, France
| | - Stéphanie Egret
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- UMR-S1077, Caen University Hospital, Caen, France
| | - Audrey Perrotin
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- UMR-S1077, Caen University Hospital, Caen, France
| | - Serge Belliard
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- Neurology Department, Pontchaillou University Hospital, Rennes, France
| | - Vincent de La Sayette
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- UMR-S1077, Caen University Hospital, Caen, France
| | - Francis Eustache
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- UMR-S1077, Caen University Hospital, Caen, France
| | - Béatrice Desgranges
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- UMR-S1077, Caen University Hospital, Caen, France
| | - Gaël Chételat
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- UMR-S1077, Caen University Hospital, Caen, France
| | - Géraldine Rauchs
- U1077, INSERM, GIP Cyceron, Caen, France
- UMR-S1077, University of Caen Normandy, Caen, France
- UMR-S1077, Ecole Pratique des Hautes Etudes, Caen, France
- UMR-S1077, Caen University Hospital, Caen, France
| |
Collapse
|
45
|
Le Guennec L, Maisonobe T, Choquet S, Massein A, Azoulay-Cayla A, Villain N, Archambaud F, Hoang-Xuan K, Idbaih A. Neurolymphomatosis as a relapse of primary cerebral nervous system lymphoma. Leuk Lymphoma 2016; 58:729-731. [PMID: 27686620 DOI: 10.1080/10428194.2016.1211277] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Affiliation(s)
- Loïc Le Guennec
- a Service de Neurologie 2-Mazarin , AP-HP, Groupe Hospitalier Pitié-Salpêtrière , Paris , France
| | - Thierry Maisonobe
- b Service de Neurophysiologie , AP-HP, Groupe Hospitalier Pitié-Salpêtrière , Paris , France
| | - Sylvain Choquet
- c Service D'Hématologie , AP-HP, Groupe Hospitalier Pitié-Salpêtrière , Paris , France
| | - Audrey Massein
- d Service de Radiologie , AP-HP, Groupe Hospitalier Pitié-Salpêtrière , Paris , France
| | - Arièle Azoulay-Cayla
- b Service de Neurophysiologie , AP-HP, Groupe Hospitalier Pitié-Salpêtrière , Paris , France
| | - Nicolas Villain
- a Service de Neurologie 2-Mazarin , AP-HP, Groupe Hospitalier Pitié-Salpêtrière , Paris , France
| | | | - Khe Hoang-Xuan
- a Service de Neurologie 2-Mazarin , AP-HP, Groupe Hospitalier Pitié-Salpêtrière , Paris , France.,f Inserm, U 1127 , Paris , France.,g CNRS, UMR 7225 , Paris , France.,h Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127 , Paris , France.,i Institut Du Cerveau Et de La Moelle Épinière, ICM , Paris , France
| | - Ahmed Idbaih
- a Service de Neurologie 2-Mazarin , AP-HP, Groupe Hospitalier Pitié-Salpêtrière , Paris , France.,f Inserm, U 1127 , Paris , France.,g CNRS, UMR 7225 , Paris , France.,h Sorbonne Universités, UPMC Univ Paris 06, UMR S 1127 , Paris , France.,i Institut Du Cerveau Et de La Moelle Épinière, ICM , Paris , France
| |
Collapse
|
46
|
Villain N, Picq JL, Aujard F, Pifferi F. Body mass loss correlates with cognitive performance in primates under acute caloric restriction conditions. Behav Brain Res 2016; 305:157-63. [PMID: 26952885 DOI: 10.1016/j.bbr.2016.02.037] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/09/2016] [Revised: 02/24/2016] [Accepted: 02/28/2016] [Indexed: 11/24/2022]
Abstract
Brain functions are known to consume high levels of energy, thus, the integrity of cognitive performance can be drastically impacted by acute caloric restriction. In this study, we tested the impact of a 40% caloric restriction on the cognitive abilities of the grey mouse lemur (Microcebus murinus). Twenty-three male mouse lemurs were divided into two groups: 13 control animals (CTL) that were fed with 105kJ/day and 10calorie restricted (CR) animals that received 40% less food (63kJ/day) than the CTL animals. The animals were fed according to their group for 19days. Before treatment, we assessed baseline associative learning capacities, resting metabolic rates and locomotor performance of both animal groups. After treatment, we tested the same functions as well as long-term memory. Our results showed that CR animals had lower learning performance following caloric restriction. The effects of caloric restriction on memory recall varied and depended on the metabolism of the individual animal. Body mass loss was linked to memory test performance in the CR group, and lower performance was observed in individuals losing the most weight. While CR was observed to negatively impact learning, locomotor capacities were preserved in CR animals, and there were higher resting metabolic rates in the CR group. Our data reinforce the strong link between energy allocation and brain function, and suggest that in the context of food shortage, learning capacities could be a limiting parameter in the adaptation to a changing environment.
Collapse
Affiliation(s)
- N Villain
- UMR CNRS MNHN 7179, Adaptive Mechanisms and Evolution (MECADEV), 1 Avenue du Petit Château, 91800 Brunoy, France
| | - J-L Picq
- Laboratoire de Psychopathologie et de Neuropsychologie, E.A. 2027, Université Paris 8, 2 Rue de la Liberté, 93000 St Denis, France; Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Neurodegenerative Diseases Laboratory, F-92265 Fontenay-aux-Roses, France; Commissariat à l'Energie Atomique et aux Energies Alternatives (CEA), Département des Sciences du Vivant (DSV), Institut d'Imagerie Biomédicale (I2BM), MIRCen, F-92265 Fontenay-aux-Roses, France
| | - F Aujard
- UMR CNRS MNHN 7179, Adaptive Mechanisms and Evolution (MECADEV), 1 Avenue du Petit Château, 91800 Brunoy, France
| | - F Pifferi
- UMR CNRS MNHN 7179, Adaptive Mechanisms and Evolution (MECADEV), 1 Avenue du Petit Château, 91800 Brunoy, France.
| |
Collapse
|
47
|
Picq JL, Villain N, Gary C, Pifferi F, Dhenain M. Jumping Stand Apparatus Reveals Rapidly Specific Age-Related Cognitive Impairments in Mouse Lemur Primates. PLoS One 2015; 10:e0146238. [PMID: 26716699 PMCID: PMC4696676 DOI: 10.1371/journal.pone.0146238] [Citation(s) in RCA: 22] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/10/2015] [Accepted: 12/15/2015] [Indexed: 11/30/2022] Open
Abstract
The mouse lemur (Microcebus murinus) is a promising primate model for investigating normal and pathological cerebral aging. The locomotor behavior of this arboreal primate is characterized by jumps to and from trunks and branches. Many reports indicate insufficient adaptation of the mouse lemur to experimental devices used to evaluate its cognition, which is an impediment to the efficient use of this animal in research. In order to develop cognitive testing methods appropriate to the behavioral and biological traits of this species, we adapted the Lashley jumping stand apparatus, initially designed for rats, to the mouse lemur. We used this jumping stand apparatus to compare performances of young (n = 12) and aged (n = 8) adults in acquisition and long-term retention of visual discriminations. All mouse lemurs completed the tasks and only 25 trials, on average, were needed to master the first discrimination problem with no age-related differences. A month later, all mouse lemurs made progress for acquiring the second discrimination problem but only the young group reached immediately the criterion in the retention test of the first discrimination problem. This study shows that the jumping stand apparatus allows rapid and efficient evaluation of cognition in mouse lemurs and demonstrates that about half of the old mouse lemurs display a specific deficit in long-term retention but not in acquisition of visual discrimination.
Collapse
Affiliation(s)
- Jean-Luc Picq
- Laboratoire de psychopathologie et de neuropsychologie, E.A. 2027, Université Paris 8, 2 rue de la liberté, 93000 St Denis, France
- Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Neurodegenerative Diseases Laboratory, F-92265 Fontenay-aux-Roses, France
- Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Département des Sciences du Vivant (DSV), Institut d’Imagerie Biomédicale (I2BM), MIRCen, F-92265 Fontenay-aux-Roses, France
- * E-mail:
| | - Nicolas Villain
- CNRS UMR 7179, MNHN, Adaptive Mechanisms and Evolution (MECADEV), 1 Av du petit château, 91800 Brunoy, France
| | - Charlotte Gary
- Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Neurodegenerative Diseases Laboratory, F-92265 Fontenay-aux-Roses, France
- Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Département des Sciences du Vivant (DSV), Institut d’Imagerie Biomédicale (I2BM), MIRCen, F-92265 Fontenay-aux-Roses, France
| | - Fabien Pifferi
- CNRS UMR 7179, MNHN, Adaptive Mechanisms and Evolution (MECADEV), 1 Av du petit château, 91800 Brunoy, France
| | - Marc Dhenain
- Centre National de la Recherche Scientifique (CNRS), Université Paris-Sud, Université Paris-Saclay UMR 9199, Neurodegenerative Diseases Laboratory, F-92265 Fontenay-aux-Roses, France
- Commissariat à l’Energie Atomique et aux Energies Alternatives (CEA), Département des Sciences du Vivant (DSV), Institut d’Imagerie Biomédicale (I2BM), MIRCen, F-92265 Fontenay-aux-Roses, France
| |
Collapse
|
48
|
Yger M, Villain N, Belkacem S, Bertrand A, Rosso C, Crozier S, Samson Y, Dormont D. [Contribution of arterial spin labeling to the diagnosis of sudden and transient neurological deficit]. Rev Neurol (Paris) 2014; 171:161-5. [PMID: 25555846 DOI: 10.1016/j.neurol.2014.10.014] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/23/2014] [Revised: 08/31/2014] [Accepted: 10/08/2014] [Indexed: 10/24/2022]
Abstract
MRI is the gold standard exploration for sudden transient neurological events. If diffusion MRI is negative, there may be a diagnostic doubt between transient ischemic attack and other causes of transient neurological deficit. We illustrate how sequence arterial spin labeling (ASL), which evaluates cerebral perfusion, contributes to the exploration of transient neurological events. An ASL sequence was performed in seven patients with a normal diffusion MRI explored for a transient deficit. Cortical hyperperfusion not systematized to an arterial territory was found in three and hypoperfusion systematized to an arterial territory in four. ASL helped guide early management of these patients.
Collapse
Affiliation(s)
- M Yger
- Service d'urgences cérébrovasculaires, groupe hospitalier Pitié-Salpétrière, 47, boulevard de l'Hôpital, 75013 Paris, France.
| | - N Villain
- Service d'urgences cérébrovasculaires, groupe hospitalier Pitié-Salpétrière, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - S Belkacem
- Service de neuroradiologie diagnostique et fonctionnelle, groupe hospitalier Pitié-Salpétrière, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - A Bertrand
- Service de neuroradiologie diagnostique et fonctionnelle, groupe hospitalier Pitié-Salpétrière, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - C Rosso
- Service d'urgences cérébrovasculaires, groupe hospitalier Pitié-Salpétrière, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - S Crozier
- Service d'urgences cérébrovasculaires, groupe hospitalier Pitié-Salpétrière, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - Y Samson
- Service d'urgences cérébrovasculaires, groupe hospitalier Pitié-Salpétrière, 47, boulevard de l'Hôpital, 75013 Paris, France
| | - D Dormont
- Service de neuroradiologie diagnostique et fonctionnelle, groupe hospitalier Pitié-Salpétrière, 47, boulevard de l'Hôpital, 75013 Paris, France
| |
Collapse
|
49
|
Prakosa A, Sermesant M, Allain P, Villain N, Rinaldi CA, Rhode K, Razavi R, Delingette H, Ayache N. Cardiac electrophysiological activation pattern estimation from images using a patient-specific database of synthetic image sequences. IEEE Trans Biomed Eng 2014; 61:235-45. [PMID: 24058008 DOI: 10.1109/tbme.2013.2281619] [Citation(s) in RCA: 14] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
Abstract
While abnormal patterns of cardiac electrophysiological activation are at the origin of important cardiovascular diseases (e.g., arrhythmia, asynchrony), the only clinically available method to observe detailed left ventricular endocardial surface activation pattern is through invasive catheter mapping. However, this electrophysiological activation controls the onset of the mechanical contraction; therefore, important information about the electrophysiology could be deduced from the detailed observation of the resulting motion patterns. In this paper, we present the study of this inverse cardiac electrokinematic relationship. The objective is to predict the activation pattern knowing the cardiac motion from the analysis of cardiac image sequences. To achieve this, we propose to create a rich patient-specific database of synthetic time series of the cardiac images using simulations of a personalized cardiac electromechanical model, in order to study this complex relationship between electrical activity and kinematic patterns in the context of this specific patient. We use this database to train a machine-learning algorithm which estimates the depolarization times of each cardiac segment from global and regional kinematic descriptors based on displacements or strains and their derivatives. Finally, we use this learning to estimate the patient’s electrical activation times using the acquired clinical images. Experiments on the inverse electrokinematic learning are demonstrated on synthetic sequences and are evaluated on clinical data with promising results. The error calculated between our prediction and the invasive intracardiac mapping ground truth is relatively small (around 10 ms for ischemic patients and 20 ms for nonischemic patient). This approach suggests the possibility of noninvasive electrophysiological pattern estimation using cardiac motion imaging.
Collapse
|
50
|
Morel N, Villain N, Rauchs G, Gaubert M, Piolino P, Landeau B, Mézenge F, Desgranges B, Eustache F, Chételat G. Brain activity and functional coupling changes associated with self-reference effect during both encoding and retrieval. PLoS One 2014; 9:e90488. [PMID: 24608131 PMCID: PMC3946483 DOI: 10.1371/journal.pone.0090488] [Citation(s) in RCA: 24] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/05/2013] [Accepted: 01/31/2014] [Indexed: 11/29/2022] Open
Abstract
Information that is processed with reference to oneself, i.e. Self-Referential Processing (SRP), is generally associated with better remembering compared to information processed in a condition not related to oneself. This positive effect of the self on subsequent memory performance is called as Self-Reference Effect (SRE). The neural basis of SRE is still poorly understood. The main goal of the present work was thus to highlight brain changes associated with SRE in terms of activity and functional coupling and during both encoding and retrieval so as to assess the relative contribution of both processes to SRE. For this purpose, we used an fMRI event-related self-referential paradigm in 30 healthy young subjects and measured brain activity during both encoding and retrieval of self-relevant information compared to a semantic control condition. We found that SRE was associated with brain changes during the encoding phase only, including both greater activity in the medial prefrontal cortex and hippocampus, and greater functional coupling between these brain regions and the posterior cingulate cortex. These findings highlight the contribution of brain regions involved in both SRP and episodic memory and the relevance of the communication between these regions during the encoding process as the neural substrates of SRE. This is consistent with the idea that SRE reflects a positive effect of the reactivation of self-related memories on the encoding of new information in episodic memory.
Collapse
Affiliation(s)
- Nastassja Morel
- Inserm, U1077, Caen, France
- Université de Caen Basse-Normandie, UMR-S1077, Caen, France
- Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France
- CHU de Caen, U1077, Caen, France
| | - Nicolas Villain
- Inserm, U1077, Caen, France
- Université de Caen Basse-Normandie, UMR-S1077, Caen, France
- Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France
- CHU de Caen, U1077, Caen, France
| | - Géraldine Rauchs
- Inserm, U1077, Caen, France
- Université de Caen Basse-Normandie, UMR-S1077, Caen, France
- Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France
- CHU de Caen, U1077, Caen, France
| | - Malo Gaubert
- Inserm, U1077, Caen, France
- Université de Caen Basse-Normandie, UMR-S1077, Caen, France
- Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France
- CHU de Caen, U1077, Caen, France
| | - Pascale Piolino
- Université de Paris Descartes, Laboratoire Mémoire et Cognition, Institut de Psychologie, Paris, France
- Inserm, U 894, Centre de Psychiatrie et Neurosciences, Paris, France
| | - Brigitte Landeau
- Inserm, U1077, Caen, France
- Université de Caen Basse-Normandie, UMR-S1077, Caen, France
- Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France
- CHU de Caen, U1077, Caen, France
| | - Florence Mézenge
- Inserm, U1077, Caen, France
- Université de Caen Basse-Normandie, UMR-S1077, Caen, France
- Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France
- CHU de Caen, U1077, Caen, France
| | - Béatrice Desgranges
- Inserm, U1077, Caen, France
- Université de Caen Basse-Normandie, UMR-S1077, Caen, France
- Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France
- CHU de Caen, U1077, Caen, France
| | - Francis Eustache
- Inserm, U1077, Caen, France
- Université de Caen Basse-Normandie, UMR-S1077, Caen, France
- Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France
- CHU de Caen, U1077, Caen, France
| | - Gaël Chételat
- Inserm, U1077, Caen, France
- Université de Caen Basse-Normandie, UMR-S1077, Caen, France
- Ecole Pratique des Hautes Etudes, UMR-S1077, Caen, France
- CHU de Caen, U1077, Caen, France
| |
Collapse
|